var title_f7_61_8144="VSD malalignment of long axis 2D";
var content_f7_61_8144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1186px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/81875/VSD_malalign_long_ax_movie.mp4?title=VSD+malalignment+of+long+axis+2D\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    VSD malalignment of long axis 2D",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aortic override and the relationship between the moving aortic valve apparatus and the trabecular and displaced conal portions of the septum are demonstrated in this parasternal long axis view.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; AO: aorta; LA: left atrium; CS: conal septum; IVS: trabecular portion of interventricular septum; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8144=[""].join("\n");
var outline_f7_61_8144=null;
var title_f7_61_8145="ILS contrast CT";
var content_f7_61_8145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography showing an intralobar pulmonary sequestration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography of the chest showing an intralobar pulmonary sequestration (ILS). The sequestration is seen as a 3.5&nbsp;x 3&nbsp;x 2.5 cm soft tissue mass located immediately above the diaphragm on the left side of the chest. A large artery from the descending aorta was identified during the study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8145=[""].join("\n");
var outline_f7_61_8145=null;
var title_f7_61_8146="CDC weight for stature boys 2 to 5 years";
var content_f7_61_8146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Weight-for-stature percentiles for boys 2 to 5 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 680px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8146=[""].join("\n");
var outline_f7_61_8146=null;
var title_f7_61_8147="Anatomic position";
var content_f7_61_8147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Anatomic position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary, 27th ed. Baltimore: Lippincott Williams &amp; Wilkins 2000. Copyright &copy;2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8147=[""].join("\n");
var outline_f7_61_8147=null;
var title_f7_61_8148="CT Grade V renal injury";
var content_f7_61_8148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT of Grade V renal injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This CT image demonstrates severe injury to the right kidney, which is surrounded by a large amount of blood (arrow). In contrast, the left kidney fills uniformly with IV dye and shows no obvious sign of injury (arrow-head).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Runyon, MD, FAAEM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8148=[""].join("\n");
var outline_f7_61_8148=null;
var title_f7_61_8149="Alosetron: Drug information";
var content_f7_61_8149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"29\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alosetron: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/45/14036?source=see_link\">",
"    see \"Alosetron: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12824192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotronex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Selective 5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Irritable bowel syndrome (IBS):",
"     </b>",
"     Females: Oral: Initial: 0.5 mg twice daily for 4 weeks, with or without food; if tolerated, but response is inadequate, may be increased after 4 weeks to 1 mg twice daily. If response is inadequate after 4 weeks of 1 mg twice-daily dosing, discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Dosage adjustment is not required; however, postmarketing experience suggests that elderly patients may be at greater risk for complications of constipation.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F131925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments recommended in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F131926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate dysfunction (Child-Pugh score &le;9): Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe dysfunction (Child-Pugh score &ge;10): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13254978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Patients experiencing constipation with 0.5 mg twice daily should discontinue therapy until constipation resolves. Therapy may be reinitiated at 0.5 mg once daily. Discontinue immediately if constipation recurs at lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ischemic colitis:",
"     </b>",
"     Discontinue therapy immediately; do not restart",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotronex&reg;: 0.5 mg, 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11216844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to the medication is restricted. Physicians must enroll in the Prometheus Prescribing Program for Lotronex&reg; (www.lotronexppl.com or 1-888-423-5227) in order to prescribe this medication. Program stickers must be affixed to all prescriptions; no phone, fax, or computerized prescriptions are permitted with this program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088624.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088624.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have failed to respond to conventional therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lotronex&reg; may be confused with Lovenox&reg;, Protonix&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Constipation (dose related; 9% to 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (&ge;3%), headache (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort and pain (1% to 7%), nausea (6%), gastrointestinal discomfort and pain (5%), gastroenteritis (&ge;3%), vomiting (&ge;3%), diarrhea (2% to 3%), flatulence (1% to 3%), hemorrhoids (1% to 3%), abdominal distention (2%), regurgitation and reflux (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (&ge;3%), nasopharyngitis (&ge;3%), upper respiratory tract infection (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;1% (Limited to important or life-threatening): Allergic skin reactions, alopecia, anxiety, arrhythmia, bilirubin level changes, bladder inflammation, bone pain, breathing disorder, cholecystitis, cognitive function disorders, confusion, cramps, colitis, depression, dermatitis, diaphoresis, diverticulitis, dyspepsia, extrasystoles, fluid disturbances, GI impaction, GI intussusception, GI lesions, GI motility decreased, GI obstructions, GI perforation, GI spasms, GI ulceration, hematoma, hemorrhage, hepatitis, hyperacidity, hyper-/hypoglycemia, hypertension, hypnagogic effects, hypoesthesia, hypothalamus/pituitary dysfunction, ileus, ischemic colitis, memory effects, muscle pain/stiffness, occult stools, pain, proctitis, rash, RBC/hemoglobin defects, sedation, sexual dysfunction, skeletal pain, small bowel mesenteric ischemia, tachyarrhythmia, temperature regulation impairment, tremor, ulcerative colitis, urinary frequency, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not start treatment in patients who are constipated. History of severe or chronic constipation or sequelae from constipation; history of ischemic colitis, intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, adhesions, diverticulitis, Crohn's disease, ulcerative colitis, severe hepatic impairment, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; patients unable to understand or comply with &ldquo;Patient-Physician&rdquo; agreement; concomitant administration with fluvoxamine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation:",
"     <b>",
"      [U.S. Boxed Warning]: Discontinue immediately in patients who develop constipation; serious complications of constipation have been infrequently reported (obstruction, ileus, perforation, impaction, toxic megacolon, secondary ischemia).",
"     </b>",
"     Constipation is a frequent, dose-related side effect; risk for complications from constipation may be increased in elderly, debilitated patients, or with concurrent use of other medications which decrease GI motility. Nonsevere constipation may be managed by temporarily interrupting therapy. Do not initiate in patients with constipation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic colitis:",
"     <b>",
"      [U.S. Boxed Warning]: Acute ischemic colitis has been reported during treatment.",
"     </b>",
"     Discontinue and evaluate immediately in patients who experience rectal bleeding, bloody diarrhea, or a sudden worsening of abdominal pain, and do not restart therapy if ischemic colitis is diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in mild-to-moderate hepatic impairment (Child-Pugh score &le;9);  contraindicated in severe impairment (Child-Pugh score &ge;10).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly due to increased risk of complications from constipation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Only indicated for women with severe diarrhea-predominant irritable bowel syndrome with inadequate response to conventional therapy",
"     </b>",
"     who have chronic IBS symptoms (lasting &ge;6 months) and  are without anatomic or biochemical abnormalities of the GI tract. Severe diarrhea-predominant IBS includes at least one of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, and disability or restriction of daily activities due to IBS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Should only be prescribed by physicians enrolled in the Prometheus Prescribing Program for Lotronex&reg;. Patients must read and sign a &ldquo;Patient-Physician&rdquo; agreement before receiving the initial prescription.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F131932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of Alosetron.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F131917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: When administered with food, absorption may be reduced by ~25%.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Alosetron should be used in pregnant women only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F131906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies indicate that alosetron and/or metabolites are excreted in breast milk. It is not known if alosetron in excreted in human milk. Caution should be used in administering alosetron to a nursing woman.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F131907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F131904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lotronex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (30): $570.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $1016.15",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alosetron is a potent and selective antagonist of a subtype of the serotonin 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor. 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptors are ligand-gated ion channels extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels affect the regulation of visceral pain, colonic transit, and gastrointestinal secretions. In patients with irritable bowel syndrome, blockade of these channels may reduce pain, abdominal discomfort, urgency, and diarrhea.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 65-95 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive hepatic metabolism via CYP2C9, 3A4, and 1A2. Thirteen metabolites have been detected in the urine. Biological activity of these metabolites in unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Mean: 50% to 60% (range: 30% to &gt;90%); decreased with food (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (74%, 13% of total dose as unchanged drug); feces (11%, 1% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Koch KM, Corrigan BW, Manzo J, et al, &ldquo;Alosetron Repeat Dose Pharmacokinetics, Effects on Enzyme Activities, and Influence of Demographic Factors,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2004, 20(2):223-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8149/abstract-text/15233703/pubmed\" id=\"15233703\" target=\"_blank\">",
"        15233703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9299 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8149=[""].join("\n");
var outline_f7_61_8149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708584\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824192\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131937\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131923\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131924\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131925\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131926\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13254978\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131897\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131882\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11216844\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874546\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131900\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131899\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131944\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131935\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131903\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131885\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131932\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131890\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131917\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131892\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131905\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131928\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131906\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131907\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131904\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131884\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131902\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/45/14036?source=related_link\">",
"      Alosetron: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_61_8150="Dactinomycin: Pediatric drug information";
var content_f7_61_8150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dactinomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"    see \"Dactinomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/5/43092?source=see_link\">",
"    see \"Dactinomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmegen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmegen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"      see \"Dactinomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be based on body surface area in obese or edematous patients. Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Medication orders for dactinomycin are commonly written in MICROgrams (eg, 150 mcg) although many regimens list the dose in MILLIgrams (eg, mg/kg or mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). The dose intensity per 2-week cycle for adults and children should not exceed 15 mcg/kg/day for 5 days or 400-600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children &gt;6 months: I.V.: Usual dose: 15 mcg/kg/day for 5 days every 3-6 weeks or 400-600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wilms' tumor, rhabdomyosarcoma, Ewing&rsquo;s sarcoma: 15 mcg/kg/day for 5 days (in various combination regimens and schedules)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Osteosarcoma: 600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1, 2, and 3 as part of a combination chemotherapy regimen (Goorin, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults: I.V.: Usual doses: 15 mcg/kg/day for 5 days every 3-6 weeks",
"     <b>",
"      or",
"     </b>",
"     400-600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-6 weeks",
"     <b>",
"      or",
"     </b>",
"     1000 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 or 12 mcg/kg/day for 5 days (monotherapy)",
"     <b>",
"      or",
"     </b>",
"     500 mcg/dose days 1 and 2 (as part of a combination chemotherapy regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Testicular cancer: 1000 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 (as part of a combination chemotherapy regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gestational trophoblastic neoplasm: 12 mcg/kg/day for 5 days (monotherapy)",
"     <b>",
"      or",
"     </b>",
"     500 mcg/dose days 1 and 2 (as part of a combination chemotherapy regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Wilms' tumor, Ewing&rsquo;s sarcoma, rhabdomyosarcoma: 15 mcg/kg/day for 5 days (in various combination regimens and schedules)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Osteosarcoma: 600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1, 2, and 3 as part of a combination chemotherapy regimen (Goorin, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ovarian (germ cell) tumor: 500 mcg/day for 5 days every 4 weeks (Gershenson, 1985) or 300 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 4 weeks (Slayton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Regional Perfusion (dosages and techniques may vary by institution; obese patients and patients with prior chemotherapy or radiation therapy may require lower doses): Lower extremity or pelvis: 50 mcg/kg; upper extremity: 35 mcg/kg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cosmegen&reg;: 0.5 mg [contains mannitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V.: For I.V. administration only; since drug is extremely irritating to tissues,",
"     <b>",
"      do not give I.M. or SubQ",
"     </b>",
"     ; avoid extravasation; use a D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS flush before and after a dactinomycin dose to ensure venous patency; administer by slow IVP over a few minutes at a concentration not to exceed 500 mcg/mL into the side-port of a freely flowing I.V. infusion. Cellulose ester membrane filters may partially remove dactinomycin from solution and should not be used during preparation or administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, cefepime, etoposide phosphate, fludarabine, gemcitabine, granisetron, melphalan, ondansetron, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Filgrastim.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and humidity. Binds to cellulose filters, therefore, avoid in-line filtration; use of a diluent containing preservatives for reconstitution may result in a precipitate; any unused portion of the reconstituted 0.5 mg/mL solution should be discarded after 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management (either alone or in combination with other treatment modalities) of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic neoplasms, and metastatic nonseminomatous testicular tumors (FDA approved in ages &gt;6 months and adults); used in regional perfusion (palliative or adjunctive) of locally recurrent or locoregional solid tumors (sarcomas, carcinomas, and adenocarcinomas). Has also been used for treatment of soft tissue sarcoma (other than rhabdomyosarcoma).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DACTINomycin may be confused with Dacogen&reg;, DAPTOmycin, DAUNOrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Actinomycin may be confused with achromycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, lethargy, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia (reversible), cheilitis, erythema multiforme, increased pigmentation, sloughing, or erythema of previously irradiated skin; skin eruptions , Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth retardation, hyperuricemia, hypocalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysphagia, esophagitis, GI ulceration, mucositis, nausea, pharyngitis, proctitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, febrile neutropenia, leukopenia, myelosuppression (onset: 7 days, nadir: 14-21 days, recovery: 21-28 days), neutropenia, pancytopenia, reticulocytopenia, thrombocytopenia, thrombocytopenia (immune mediated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ascites, bilirubin increased, hepatic failure, hepatitis, hepatomegaly, hepatopathy thrombocytopenia syndrome, hepatotoxicity, liver function test abnormality, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Erythema, edema, epidermolysis, pain, tissue necrosis, and ulceration (following extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, infection, sepsis (including neutropenic sepsis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dactinomycin or any component; patients with chickenpox or herpes zoster; avoid in infants &lt;6 months of age since the incidence of adverse effects is increased in infants",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dosage in patients with hepatobiliary dysfunction or in patients  receiving radiation therapy; patients receiving radiation therapy are at increased risk for gastrointestinal and myelosuppressive effects; avoid administering live virus vaccinations during therapy with dactinomycin. Erythema from prior radiation therapy may be reactivated by dactinomycin. Avoid dactinomycin use within 2 months of radiation treatment for right-sided Wilms' tumor; may increase the risk of hepatotoxicity. Regional perfusion therapy may result in local limb edema, soft tissue damage, and possible venous thrombosis; dactinomycin leakage into systemic circulation may result in hematologic toxicity, infection, impaired wound healing, and mucositis. Administer under the supervision of a physician experienced in cancer chemotherapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dactinomycin is extremely toxic; avoid inhalation of vapors or contact with skin, mucous membrane, or eyes",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; in case of accidental exposure to eyes or mucous membranes, irrigate area with water, normal saline, or balanced salt ophthalmic irrigating solution for at least 15 minutes. Avoid exposure during pregnancy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; dactinomycin may cause fetal harm when administered to pregnant women. Women of childbearing potential must be warned to avoid becoming pregnant. Dactinomycin is extremely irritating to tissues",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . If extravasation occurs during I.V. use, severe damage to soft tissue will occur leading to pain, swelling, ulceration, and necrosis. Extravasation leading to contracture of the arms has also been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reports of secondary malignancies (including leukemia) following treatment with radiation and dactinomycin have occurred; long-term observation of cancer survivors is recommended. May cause potentially fatal hepatic sinusoidal obstruction syndrome [SOS; formerly called veno-occlusive disease (VOD)]; reported incidence of veno-occlusive disease across different clinical studies is 2% to 13.5% with increased risk in children &lt;4 years of age. Monitor for signs or symptoms of hepatic VOD, including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenic effects and fetal loss. Women of childbearing potential are advised not to become pregnant. Use only when potential benefit justifies potential risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Avoid exposure during pregnancy.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, liver function tests and renal function tests; monitor for signs/symptoms of hepatic VOD, including unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt, 2004); monitor serum beta-hCG (management of gestational trophoblastic neoplasms)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to the guanine portion of DNA intercalating between guanine and cytosine base pairs blocking replication and transcription of the DNA template inhibiting RNA synthesis; causes topoisomerase-mediated single-strand breaks in DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive extravascular distribution with high concentration in nucleated cells and bone marrow; does not penetrate blood brain barrier; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 14-43 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: ~10% of dose excreted as unchanged drug in urine; 15% recovered in feces; 50% appears in bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/5/43092?source=see_link\">",
"      see \"Dactinomycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, bleeding, or bruising occurs; report immediately any pain, burning, or swelling at the infusion site. Advise women of childbearing potential to avoid becoming pregnant while receiving dactinomycin.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arndt C, Hawkins D, Anderson JR, et al, \"Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and Cyclophosphamide,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(10):1894-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/15143082 /pubmed\" id=\"15143082 \" target=\"_blank\">",
"        15143082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagshawe KD, \"High-Risk Metastatic Trophoblastic Disease,\"",
"      <i>",
"       Obstet Gynecol Clin North Am",
"      </i>",
"      , 1988, 15(3):531-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/2852333/pubmed\" id=\"2852333\" target=\"_blank\">",
"        2852333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berkowitz RS and Goldstein DP, &ldquo;Gestational Trophoblastic Disease,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1995, 76(10 Suppl):2079-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/8635004 /pubmed\" id=\"8635004 \" target=\"_blank\">",
"        8635004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carli M, Pastore G, Perilongo G, et al, &ldquo;Tumor Response and Toxicity After Single High-Dose Versus Standard Five-Day Divided Dose Dactinomycin in Childhood Rhabdomyosarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1988, 6(4):654-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/3357006 /pubmed\" id=\"3357006 \" target=\"_blank\">",
"        3357006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gershenson DM, Copeland LJ, Kavanagh JJ, et al, \"Treatment of Malignant Nondysgerminomatous Germ Cell Tumors of the Ovary With Vincristine, Dactinomycin, and Cyclophosphamide,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 1985, 56(12):2756-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/2996746 /pubmed\" id=\"2996746 \" target=\"_blank\">",
"        2996746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goorin AM, Schwartzentruber DJ, Devidas M, et al, \"Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(8):1574-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/12697883/pubmed\" id=\"12697883\" target=\"_blank\">",
"        12697883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slayton RE, Park RC, Silverberg SG, et al, \"Vincristine, Dactinomycin, and Cyclophosphamide in the Treatment of Malignant Germ Cell Tumors of the Ovary. A Gynecologic Oncology Group Study (A Final Report),\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 1985, 56(2):243-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/2988740/pubmed\" id=\"2988740\" target=\"_blank\">",
"        2988740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veal GJ, Cole M, Errington J, et al, \"Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: A United Kingdom Children's Cancer Study Group Study,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2005, 11(16):5893-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8150/abstract-text/16115931/pubmed\" id=\"16115931\" target=\"_blank\">",
"        16115931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13202 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8150=[""].join("\n");
var outline_f7_61_8150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708689\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156394\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156395\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046864\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046857\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156372\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156356\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046868\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156438\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046860\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046867\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156441\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156437\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046871\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046856\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046855\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299119\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156365\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156368\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156380\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046863\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046854\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046870\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046862\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13202\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13202|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=related_link\">",
"      Dactinomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/5/43092?source=related_link\">",
"      Dactinomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_61_8151="Factor IX concentrates: Drug information";
var content_f7_61_8151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Factor IX concentrates: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21430?source=see_link\">",
"    see \"Factor IX concentrates: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/56/28548?source=see_link\">",
"    see \"Factor IX concentrates: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16264034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AlphaNine&reg; SD;",
"     </li>",
"     <li>",
"      Mononine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16264035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Immunine&reg; VH",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16264038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16321187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      NOTE:",
"     </b>",
"     Contains",
"     <b>",
"      nondetectable levels of factors II, VII, and X",
"     </b>",
"     . Therefore,",
"     <b>",
"      NOT INDICATED",
"     </b>",
"     for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):",
"     </b>",
"     I.V.:",
"     <i>",
"      AlphaNine&reg; SD, Mononine&reg;:",
"     </i>",
"     Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Refer to product information for specific manufacturer recommended dosing. Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Formula to determine units required to obtain desired factor IX level:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level increase&rdquo;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1 unit/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For example, to attain an 80% level in a 70 kg patient who has a baseline level of 20%: Number of factor IX units needed = 70 kg x 60% x 1 unit/kg = 4200 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      World Federation of Hemophilia (WFH) Guidelines (2012): Note:",
"     </b>",
"     The following recommendations may vary from those found within prescribing information or practitioner preference.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     15-30 units/kg twice weekly (WFH, 2012 [Utrecht protocol])",
"     <b>",
"      or",
"     </b>",
"     25-40 units/kg twice weekly (WFH, 2012 [Malm�� protocol])",
"     <b>",
"      or",
"     </b>",
"     40-100 units/kg administered 2-3 times weekly (National Hemophilia Foundation, MASAC recommendation, 2007); optimum regimen has yet to be defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Treatment:",
"     </i>",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      2012 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists):",
"     </caption>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Site of Hemorrhage/Clinical Situation",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Desired Factor IX Level to Maintain",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Duration",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Joint",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         40-60 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1-2 days, may be longer if response is inadequate",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Superficial muscle/no neurovascular compromise",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         40-60 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 days, sometimes longer if response is inadequate",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         60-80 units/dL",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         30-60 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         1-2 days",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         3-5 days, sometimes longer as secondary prophylaxis during physiotherapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          CNS/head",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         60-80 units/dL",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         30 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         1-7 days",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         8-21 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Throat and neck",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         60-80 units/dL",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         30 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         1-7 days",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         8-14 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Gastrointestinal",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         60-80 units/dL",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         30 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Initial:",
"         </i>",
"         7-14 days",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Maintenance:",
"         </i>",
"         Not specified",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Renal",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         40 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Deep laceration",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         40 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Surgery (major)",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Preop:",
"         </i>",
"         60-80 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Postop:",
"         </i>",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         40-60 units/dL",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         30-50 units/dL",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         20-40 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Postop:",
"         </i>",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         1-3 days",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         4-6 days",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         7-14 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Surgery (minor)",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Preop:",
"         </i>",
"         50-80 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Postop:",
"         </i>",
"         30-80 units/dL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Postop:",
"         </i>",
"         1-5 days depending  on procedure type",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Continuous infusion (for patients who require prolonged periods of treatment [eg, intracranial hemorrhage or surgery] to avoid peaks and troughs associated with intermittent infusions) (Batorova, 2002; Poon, 2012; Rickard, 1995; WFH, 2012):",
"     </i>",
"     Following initial bolus to achieve the desired factor IX level: Initiate 4-6 units/kg/hour; adjust dose based on frequent factor assays and calculation of factor IX clearance at steady-state using the following equations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (plasma level in units/",
"     <b>",
"      m",
"     </b>",
"     L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/",
"     <b>",
"      m",
"     </b>",
"     L)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F16318994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21430?source=see_link\">",
"      see \"Factor IX concentrates: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      NOTE:",
"     </b>",
"     Contains",
"     <b>",
"      nondetectable levels of factors II, VII, and X",
"     </b>",
"     . Therefore,",
"     <b>",
"      NOT INDICATED",
"     </b>",
"     for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):",
"     </b>",
"     Infants, Children, and Adolescents: I.V.:",
"     <i>",
"      AlphaNine&reg; SD, Mononine&reg;:",
"     </i>",
"     Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Refer to product information for specific manufacturer recommended dosing. Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Formula to determine units required to obtain desired factor IX level:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level increase&rdquo;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1 unit/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For example, to attain an 80% level in a 70 kg patient who has a baseline level of 20%: Number of factor IX units needed = 70 kg x 60% x 1 unit/kg = 4200 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      World Federation of Hemophilia (WFH) Guidelines (2012):",
"     </b>",
"     Infants, Children, and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16318995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16321198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AlphaNine&reg; SD: 500 units, 1000 units, 1500 units [contains factor II (may have trace amounts), factor VII (may have trace amounts), factor X (may have trace amounts), polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mononine&reg;: 500 units, 1000 units [contains factor II (may have trace amounts), factor VII (may have trace amounts), factor X (may have trace amounts), mouse protein, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16264037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16321188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solution should be infused at room temperature.",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. administration only: Should be infused",
"     <b>",
"      slowly over several minutes",
"     </b>",
"     : Rate of administration should be determined by the response and comfort of the patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AlphaNine&reg; SD: Administer I.V. at a rate not exceeding 10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mononine&reg;: Administer I.V. at a rate of ~2 mL/minute. Administration rates of up to 225",
"     <b>",
"      units",
"     </b>",
"     /minute have been regularly tolerated without incident (when reconstituted as directed to ~100 units/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     World Federation of Hemophilia (WFH) recommendations: Infuse at rate of 3 mL/minute for adults or 100",
"     <b>",
"      units",
"     </b>",
"     /minute for young children; may also administer as a continuous infusion in select patients. With patients who have had allergic reactions during factor IX infusion, administration of hydrocortisone prior to infusion may be necessary (WFH, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16264042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and control of bleeding in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      NOTE:",
"     </b>",
"     Contains",
"     <b>",
"      nondetectable levels of factors II, VII, and X",
"     </b>",
"     . Therefore,",
"     <b>",
"      NOT INDICATED",
"     </b>",
"     for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16264032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;\">",
"       Factor IX may be confused with Factor IX Complex",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16265558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cyanosis, flushing, hypotension, chest tightness, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, drowsiness, fever (including transient fever following rapid administration), headache, lethargy, lightheadedness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, photosensitivity reaction, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Disseminated intravascular coagulation (DIC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Cellulitis, discomfort, pain, phlebitis, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck tightness, paresthesia, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis, asthma, cough, dyspnea, hypoxia, laryngeal edema, lung disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, burning sensation in jaw/skull, factor IX inhibitor development, hypersensitivity reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: HAV seroconversion, inadequate response/recovery, nephrotic syndrome (associated with immune tolerance induction), parvovirus B19 seroconversion, renal infarction, superior vena cava syndrome (neonates)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16264049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AlphaNine SD&reg;: There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mononine&reg;: Hypersensitivity to mouse protein",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16264050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10-20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10-20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombotic events: Observe closely for signs or symptoms of intravascular coagulation or thrombosis; risk is generally associated with the use of factor IX complex concentrates (containing therapeutic amounts of additional factors); however, potential risk exists with use of factor IX products (containing only factor IX). Use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the risk of thromboembolic complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma. Despite purification methods (AlphaNine&reg; SD - solvent detergent treated/virus filtered; Mononine&reg; - virus filtered); products may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Contains",
"     <b>",
"      nondetectable levels of factors II, VII, and X.",
"     </b>",
"     Therefore,",
"     <b>",
"      NOT INDICATED",
"     </b>",
"     for replacement therapy of any other clotting factor besides factor IX. In addition, factor IX concentrate is",
"     <b>",
"      NOT INDICATED",
"     </b>",
"     for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), hemophilia A patients with factor VIII inhibitors, or patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune tolerance induction: Safety and efficacy have not been established in immune tolerance induction with factor IX products. Nephrotic syndrome has occurred following immune tolerance induction in patients with factor IX inhibitors and a history of allergic reactions to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16369064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16369062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminocaproic Acid: May enhance the adverse/toxic effect of Factor IX (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16264047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16264048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than a nonpregnant woman.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (AlphaNine SD Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $1.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 unit (1): $1.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Mononine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 unit (1): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16321190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Factor IX levels (measure 15 minutes after infusion to verify calculated doses [WFH, 2012]), aPTT, BP, HR, signs of hypersensitivity reactions; screen for factor IX inhibitors when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days within 4 weeks of the last infusion, or at the following intervals (WFH, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: Screen for inhibitors every 5 exposure days until 20 exposure days, every 10 exposure days between 21-50 exposure days, and at a minimum of twice a year until 150 exposure days is reached.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults (with &gt;150 exposure days apart from a 6-12 monthly review): Screen for inhibitors when suboptimal response occurs.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F16265653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Average normal factor IX levels are 50% to 150%; patients with severe hemophilia B will have levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16265581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16265654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: IX component: ~21-25 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batorova A and Martinowitz U, \"Continuous Infusion of Coagulation Factors,\"",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2002, 8(3):170-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/12010406/pubmed\" id=\"12010406\" target=\"_blank\">",
"        12010406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;Guidelines for Emergency Department Management of Individuals With Hemophilia,&rdquo; 2006. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/175.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders,&rdquo; 2010. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac190.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding),&rdquo; 2007. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poon MC and Card R, \"Hemophilia Management in Transfusion Medicine,\"",
"      <i>",
"       Transfus Apher Sci",
"      </i>",
"      , 2012, 46(3):299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/22503305/pubmed\" id=\"22503305\" target=\"_blank\">",
"        22503305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rickard KA, &ldquo;Guidelines for Therapy and Optimal Dosages of Coagulation Factors for Treatment of Bleeding and Surgery in Haemophilia,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 1995, 1(Suppl 1):8-13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shibata M, Shima M, Misu H, et al, \"Management of Haemophilia B Inhibitor Patients With Anaphylactic Reactions to FIX Concentrates,\"",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2003, 9(3):269-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/12694516/pubmed\" id=\"12694516\" target=\"_blank\">",
"        12694516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shord SS and Lindley CM, \"Coagulation Products and Their Uses,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(15):1403-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/10938981/pubmed\" id=\"10938981\" target=\"_blank\">",
"        10938981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al, on behalf of the World Federation of Hemophilia (WFH), \"Guidelines for the Management of Hemophilia,\"",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2013, 19(1):e1-47. Available at file://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2012.02909.x/pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/22776238/pubmed\" id=\"22776238\" target=\"_blank\">",
"        22776238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Srivastava A, \"Dose and Response in Haemophilia--Optimization of Factor Replacement Therapy,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2004, 127(1):12-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/15384973/pubmed\" id=\"15384973\" target=\"_blank\">",
"        15384973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Varon D and Martinowitz U, \"Continuous Infusion Therapy in Haemophilia,\"",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 1998, 4(4):431-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/9873771/pubmed\" id=\"9873771\" target=\"_blank\">",
"        9873771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White GC 2nd, Beebe A, and Nielsen B, \"Recombinant Factor IX,\"",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1997, 78(1):261-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8151/abstract-text/9198163/pubmed\" id=\"9198163\" target=\"_blank\">",
"        9198163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88578 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8151=[""].join("\n");
var outline_f7_61_8151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264034\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264035\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264038\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321187\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16318994\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16318995\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321198\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264037\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321188\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264042\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264032\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265558\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264049\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264050\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369064\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369062\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264047\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264048\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570473\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321190\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265653\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265581\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265654\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/56/28548?source=related_link\">",
"      Factor IX concentrates: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21430?source=related_link\">",
"      Factor IX concentrates: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_61_8152="Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information";
var content_f7_61_8152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2a: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/3/21558?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2a: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1029834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Interferon",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1029863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"      see \"Pegylated interferon (peginterferon) alfa-2a: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;5 years and Adolescents:",
"     <b>",
"      Chronic hepatitis C (CHC):",
"     </b>",
"     SubQ: 104 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly; maximum dose: 180 mcg; in combination with ribavirin (Copegus&reg;) (Schwartz, 2011);",
"     <b>",
"      Note:",
"     </b>",
"     Dosing presented is mathematically equivalent to weekly dosing presented in manufacturer&rsquo;s labeling: 180 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x Body Surface Area (BSA); adolescents who reach their 18th birthday during treatment should remain on the pediatric regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration of therapy (based on genotype):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Genotype 1, 4: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Genotype 2, 3: 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic hepatitis C (monoinfection or coinfection with HIV):",
"     </b>",
"     SubQ: 180 mcg once weekly for 48 weeks as monotherapy or in combination with ribavirin (Copegus&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Duration of therapy: Monoinfection (based on genotype):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Genotypes 1, 4: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Genotypes 2, 3: 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Genotypes 5, 6: No dosing recommendations provided; data insufficient",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Duration of therapy: Coinfection with HIV: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Association for the Study of Liver Diseases (AASLD) guidelines recommendation: Adults with chronic HCV infection (Ghany, 2009): Treatment of choice: Ribavirin plus",
"     <b>",
"      peginterferon",
"     </b>",
"     ; clinical condition and ability of patient to tolerate therapy should be evaluated to determine length and/or likely benefit of therapy. Recommended treatment duration (AASLD guidelines): Genotypes 1,4: 48 weeks; Genotypes 2,3: 24 weeks; Coinfection with HIV: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic hepatitis B:",
"     </b>",
"     SubQ: 180 mcg once weekly for 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents: No dosage adjustment provided in manufacturer's labeling; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Reduce dose to 135 mcg weekly; monitor for interferon toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     End-stage renal disease (ESRD) requiring hemodialysis: 135 mcg weekly; monitor for interferon toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents:",
"     <i>",
"      Chronic Hepatitis C:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ALT &ge;5 but &lt;10 x ULN: Decrease interferon dose to 78  mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly. Monitor weekly; further modify dose if needed until ALT stabilizes or decreases (Schwartz, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing presented is mathematically equivalent to adjusted weekly dose in manufacturer&rsquo;s labeling: 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x Body Surface Area (BSA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ALT &ge;10 x ULN (persistent): Discontinue interferon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Chronic hepatitis C",
"     </i>",
"     (CHC): ALT progressively rising above baseline: Decrease dose to 135 mcg weekly",
"     <b>",
"      and",
"     </b>",
"     monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately. Therapy may resume after ALT flare subsides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Chronic hepatitis B",
"     </i>",
"     (HBV):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ALT &gt;5 x ULN: Consider decreasing dose to 135 mcg weekly or temporarily discontinuing (may resume after ALT flare subsides)",
"     <b>",
"      and",
"     </b>",
"     monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ALT &gt;10 x ULN: Consider discontinuing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Pediatric dosing adjustments shown below correspond to the following doses in manufacturer's labeling: 78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     = 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; 52 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     = 90 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; and 26 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     = 45 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     (Schwartz, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For moderate to severe adverse reactions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents: Decrease to 78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for initial dose reduction; further dose reductions  to 52 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly and then 26 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly may 	be necessary in some cases if reaction persists or recurs. Up to three dosing adjustments for toxicity may be made before discontinuation is considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: HCV, HBV infection: For moderate to severe adverse reactions: Decrease to 135 mcg/week for initial dose reduction; further dose reductions to 90 mcg/week may be necessary in some cases if reaction persists or recurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for depression (severity based upon DSM-IV criteria):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Mild depression:",
"     </i>",
"     Children, Adolescents, and Adults: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Moderate depression:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents: Initially decrease interferon dose to 78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly and based upon response of adverse effect further dose modifications may be necessary in stepwise approach; next decrease to 52 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly and then 26 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly; evaluate once weekly with an office visit at least every other week. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; may continue reduced dosing or return to normal dose. If depression remains stable, consider psychiatric evaluation and continue reduced dosing.  If symptoms worsen, considered further dosage reduction; discontinue therapy if  no improvement after three dosage reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: Decrease interferon dose to 135 mcg once weekly (or to 90 mcg once weekly); evaluate once weekly with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue with reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Severe depression:",
"     </i>",
"     Children, Adolescents, and Adults: Discontinue interferon permanently. Obtain immediate psychiatric consultation. Discontinue ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for hematological toxicity:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Management dependent upon weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neutropenia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC 750-999/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Week 1-2: Decrease dose to  78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Weeks 3-48: No modification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC 500-749/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Week 1-2: Hold dose until ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     then resume therapy at 78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly. Assess WBC weekly for 3 weeks to verify ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Weeks 3-48: Decrease dose to 78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC 250-499/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Week 1-2: Hold dose until ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     then resume dose at 52 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Weeks 3-48: Hold dose until ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     then resume dose at 78 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     or febrile neutropenia: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Thrombocytopenia:  Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Decrease dose to 52 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neutropenia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 135 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Suspend therapy until &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , then restart at 90 mcg once weekly; monitor ANC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Thrombocytopenia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 90 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue therapy",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys&reg;: 180 mcg/mL (1 mL) [contains benzyl alcohol, polysorbate 80; vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys&reg;: 135 mcg/0.5 mL (0.5 mL); 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80; autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys&reg;: 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80; prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1029868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Administer in the abdomen or thigh. Rotate injection site. Do not use if solution contains particulate matter or is discolored. Discard unused solution. Administration should be done on the same day and at approximately the same time each week.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1029856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze or shake; protect from light. The following stability information has also been reported:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intact vial: May be stored at room temperature for up to 14 days (Cohen, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prefilled syringe: May be stored at room temperature for up to 6 days (Cohen, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1029835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis C (CHC), in combination with ribavirin (unless contraindicated or significant intolerance to ribavirin) in patients with compensated liver disease and not previously treated with alfa interferons and in patients with histological evidence of cirrhosis (Child-Pugh class A) and compensated liver disease (FDA approved in ages &ge;5 years and adults); treatment of patients coinfected with CHC and clinically stable HIV disease (CD",
"     <sub>",
"      4",
"     </sub>",
"     count &gt;100 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) (FDA approved in adults); treatment (monotherapy) of HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease and evidence of viral replication and liver inflammation (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, concentration impaired, depression, dizziness, fatigue, fever, headache, insomnia, irritability, memory impaired, mood alteration, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, eczema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth suppression (children) percentile decrease (including weight, height); hyperthyroidism, hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, vomiting, xerostomia, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, platelets decreased &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , lymphopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increases 5-10 x ULN during treatment; ALT increases &gt;10 x ULN during treatment; ALT increases 5-10 x ULN after treatment; ALT increases &gt;10 x ULN after treatment; hepatic decompensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacterial infection, diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggression, anaphylaxis, angioedema, angina, aplastic anemia, arrhythmia, autoimmune disorders, bronchiolitis obliterans, bronchoconstriction, cerebral hemorrhage, chest pain, cholangitis, colitis, coma, corneal ulcer, cotton wool spots, dehydration, diabetes mellitus, endocarditis, erythema multiforme major, exertional dyspnea, exfoliative dermatitis, fatty liver, gastrointestinal bleeding, hallucination, hearing impairment, hearing loss, hemoglobin decreased, hematocrit decreased, hepatic dysfunction, hepatic graft rejection, hepatitis B flares, hyper-/hypoglycemia, hypersensitivity reactions, hypertension, influenza, interstitial pneumonitis, macular edema, MI, myositis, optic neuritis, papilledema, pancreatitis, peptic ulcer, peripheral neuropathy, pneumonia, psychiatric disorder, psychosis, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, renal graft rejection, retinal artery/vein thrombosis, retinal detachment, retinal hemorrhage, retinopathy, rheumatoid arthritis, sarcoidosis, seizures, Stevens-Johnson syndrome, substance overdose, suicidal ideation, suicide, supraventricular arrhythmia, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, triglycerides (increased), urticaria, vesiculobullous eruptions, vision decreased/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1029840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to interferon alfa, polyethylene glycol (PEG), or any component; autoimmune hepatitis; decompensated liver disease in cirrhotic patients (Child-Pugh score &gt;6); in patients with CHC and coinfected with HIV decompensated liver disease (Child-Pugh score &ge;6, class B and C); in neonates and infants due to benzyl alcohol excipient. Combination therapy with ribavirin is additionally contraindicated in pregnancy; men whose female partners are pregnant; hypersensitivity (urticaria, angioedema, bronchoconstriction, and anaphylaxis) to ribavirin any component of the tablet; hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); concurrent didanosine use",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15832439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution  in renal impairment;  clearance is decreased; if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute dosage adjustment recommended and monitor closely for signs/symptoms of interferon toxicity or laboratory abnormalities; if occur, further dosage  reductions may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with history of cardiovascular disease; hypertension, arrhythmia, chest pain, and MI have been observed with treatment; baseline (pretreatment) hematological and biochemical tests are recommended for all patients and if pre-existing cardiac abnormalities, an ECG is also recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in thyroid disease; thyroid disorders (hyper- or hypothyroidism) or exacerbations have been reported; discontinue peginterferon alfa-2a if unable to effectively manage with medication. Use with caution in diabetes mellitus; hyper-/hypoglycemia have been reported; may require adjustments in antidiabetic medications; discontinue peginterferon alfa 2a if unable to effectively manage diabetes with medication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Inhibition of growth velocity in pediatric patients may occur; in clinical trials, growth suppression of  &ge;15 percentiles on the normal growth curve was reported  for weight in 43% of pediatric patients and for height in 25% of patients after 48 weeks of therapy.  At the two-year follow up after treatment, most children had returned to their baseline growth curve percentile; monitor growth at baseline and during therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution with concurrent telbivudine therapy; peripheral neuropathy has been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Safety and efficacy have not been established in the following patient types: Failed other alpha interferon therapy; received liver or other organ transplants; been coinfected with HBV and HCV or HIV; coinfection with  HCV and HIV and a CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &lt;100 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; or treatment duration &gt;48 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1029841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause or exacerbate life-threatening neuropsychiatric disorders",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor closely; discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders. In most cases, these effects were reversible following discontinuation, but not all cases. Neuropsychiatric adverse effects include depression, suicidal ideation, suicide attempt, homicidal ideation, drug overdose, and relapse of drug addiction, and may occur in patients with or without a prior history of psychiatric disorder. Avoid use in severe psychiatric disorders; use with extreme caution in patients with a history of depression. May cause CNS effects; patients who experience dizziness, confusion, somnolence, or fatigue should use caution when performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause or exacerbate autoimmune disorders",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease. Thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis have been reported with interferon therapy; use with caution in patients with autoimmune disorders.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May  cause or aggravate infectious disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; serious and severe infections (bacterial, viral, and fungal) have been reported with treatment. Interferon therapy is commonly associated with flu-like symptoms, including fever; however, rule out other causes/infection with persistent or high fever. May cause myelosuppression (including neutropenia, thrombocytopenia, lymphopenia, aplastic anemia). Use caution with baseline neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or hemoglobin &lt;10 g/dL. Discontinue therapy (at least temporarily) if ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hepatic decompensation and death have been associated with the use of alpha interferons, including Pegasys&reg;, in cirrhotic chronic hepatitis C patients; patients coinfected with HIV and receiving highly active antiretroviral therapy have shown an increased risk. Monitor hepatic function closely during use; discontinue if decompensation occurs (Child-Pugh score &gt;6) in monoinfected patients and (Child-Pugh score &ge;6, class B and C) in patients coinfected with HIV. In hepatitis B patients, flares (transient and potentially severe increases in serum ALT) may occur during or after treatment; more frequent monitoring of LFTs and a dose reduction are recommended. Discontinue if ALT elevation continues despite dose reduction or if increased bilirubin or hepatic decompensation occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause ocular effects including decreased vision, retinal hemorrhages, retinal detachment (serous), cotton wool spots, and retinal artery or vein obstruction; discontinue if any ocular symptoms occur during use and a complete eye exam should be performed promptly. Prior to use, all patients should have a visual exam and patients with pre-existing disorders (eg, diabetic or hypertensive retinopathy) should have  periodically during therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serious cutaneous reactions, including vesiculobullous eruptions, Stevens-Johnson syndrome, and exfoliative dermatitis, have been reported (rarely) with use, with or without ribavirin therapy; discontinue with signs or symptoms of severe skin reactions. Severe acute hypersensitivity reactions have occurred rarely; prompt discontinuation is advised.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Gastrointestinal hemorrhage, ulcerative and hemorrhagic/ischemic colitis have been observed with interferon alfa treatment; may be severe and/or life-threatening; discontinue if symptoms of colitis (eg, abdominal pain, bloody diarrhea, and/or fever) develop. Colitis generally resolves within 1-3 weeks of discontinuation. Use with caution in patients with an increased risk for severe anemia (eg, spherocytosis, history of GI bleeding). May cause pancreatitis; discontinue therapy if known or suspected pancreatitis develops.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause or aggravate ischemic disorders and hemorrhagic cerebrovascular events",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; cerebrovascular events have been reported in patients without risk factors for stroke (including &lt;45 years of age); monitor closely; discontinue treatment in patients with worsening or persistent ischemia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonia, and sarcoidosis, resulting in potentially fatal respiratory failure; may recur upon rechallenge with interferons. Discontinue with unexplained pulmonary infiltrates or evidence of impaired pulmonary function. Use with caution in patients with pulmonary dysfunction or a history of pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Combination treatment with ribavirin may cause birth defects and/or fetal mortality; hemolytic anemia (which may worsen cardiac disease), genotoxicity, mutagenicity, and may possibly be carcinogenic",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Avoid pregnancy in females and female partners of male patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; combination therapy with ribavirin is contraindicated in pregnancy. Pretreatment pregnancy screening (if woman of childbearing age) is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to differences in dosage, patients should not change brands of interferon without the concurrence of their healthcare provider. Solution for injection contains benzyl alcohol and polysorbate 80 (Tween 80&reg;)  which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1029852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2a.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Peginterferon Alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C / X in combination with ribavirin (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with pegylated interferon alfa have not been conducted. Animal studies with nonpegylated interferon alfa-2b have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid.",
"     <i>",
"      In vitro",
"     </i>",
"     administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that peginterferon-alfa be used during pregnancy. Peginterferon monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Combination therapy with ribavirin may cause birth defects; avoid pregnancy in females and female partners of male patients;",
"     </b>",
"     combination therapy with ribavirin is contraindicated in pregnancy (refer to Ribavirin monograph); a pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1029870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following were used during clinical trials:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;5 years and Adolescents: Hematologic and biochemical assessments were made at weeks 1, 3, 5, and 8, and then every 4 weeks thereafter; TSH measured every 12 weeks; growth parameters (height, weight, percentiles on growth curve) (Schwarz, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 1, 2, 4, 6, and 8, and then every 4-6 weeks (more frequently if abnormal); TSH measured every 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additionally, the following baseline values were used as entrance criteria in adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &ge;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (as low as 75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     in patients with cirrhosis or 70,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     in patients with CHC coinfected with HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine &lt;1.5 times ULN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TSH and T",
"     <sub>",
"      4",
"     </sub>",
"     within normal limits or adequately controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;200 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;100 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , but &lt;200 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and HIV-1 RNA &lt;5000 copies/mL in CHC patients coinfected with HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men in CHC monoinfected patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &ge;11 g/dL for women and &ge;12 g/dL for men in CHC patients coinfected with HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Also in adults, serum HCV RNA levels (pretreatment, 12- and 24 weeks after therapy initiation, 24 weeks after completion of therapy).",
"     <b>",
"      Note:",
"     </b>",
"     Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA (Ghany, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prior to treatment, pregnancy screening should occur for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment. In combination therapy with ribavirin, pregnancy tests should continue monthly up to 6 months after discontinuation of therapy. Evaluate for depression and other psychiatric symptoms before and during therapy; baseline eye examination and periodically in patients with baseline disorders; baseline echocardiogram in patients with cardiac disease.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1029858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1029860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 50-160 hours; increased with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 72-96 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1029874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/3/21558?source=see_link\">",
"      see \"Pegylated interferon (peginterferon) alfa-2a: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication must be given by injection; follow instructions for injection and syringe/needle disposal. Avoid alcohol. Laboratory tests and ophthalmic exams prior to and during therapy are required. May cause headache; insomnia; dizziness; temporary loss of hair (will grow back after therapy); nausea or anorexia; diarrhea; weakness or fatigue; flu-like symptoms; or muscle, skeletal, or joint pain. Report any persistent nausea, vomiting, or abdominal pain; severe depression or suicide ideation; skin rash; pain, redness, or swelling at injection site; signs of infection; unusual bleeding or bruising; changes in vision; or chest pain, palpitations, or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, \"An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management and Treatment of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo;",
"      <i>",
"       J Gen Virol",
"      </i>",
"      , 1982, 59(Pt 2):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/6176680/pubmed\" id=\"6176680\" target=\"_blank\">",
"        6176680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray KF, Rodrigue JR, Gonz&aacute;lez-Peralta RP, et al, \"Design of the PEDS-C trial: Pegylated Interferon &plusmn; Ribavirin for Children With Chronic Hepatitis C Viral Infection,\"",
"      <i>",
"       Clin Trials",
"      </i>",
"      , 2007, 4(6):661-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/18042575/pubmed\" id=\"18042575\" target=\"_blank\">",
"        18042575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&rdquo; April 29, 2009, 1-90. Available at",
"      <a href=\"file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al, \"The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2011, 140(2):450-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/21036173/pubmed\" id=\"21036173\" target=\"_blank\">",
"        21036173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(6):1232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/61/8152/abstract-text/8328774/pubmed\" id=\"8328774\" target=\"_blank\">",
"        8328774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87809 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8152=[""].join("\n");
var outline_f7_61_8152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709197\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206899\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206900\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029834\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029863\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206881\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206867\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874941\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029868\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029856\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029835\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206924\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029840\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15832439\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029841\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029852\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206874\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206876\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206889\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029870\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029858\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029860\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029874\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87809|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/3/21558?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_61_8153="Overview of amblyopia";
var content_f7_61_8153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of amblyopia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/61/8153/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8153/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8153/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/61/8153/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8153/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/61/8153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8153/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/61/8153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amblyopia is a functional reduction in the visual acuity of an eye caused by disuse or misuse during the critical period of visual development. The earlier amblyopia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amblyopia risk factors are detected, the better the potential visual outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This is one of the reasons it is important to screen preschool-age children for vision problems and amblyopia. Vision screening can and should be performed by primary care clinicians. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening tests in children and adolescents\", section on 'Vision screen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the classification, diagnosis, and treatment of amblyopia is presented here. Vision assessment and strabismus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link\">",
"     \"Evaluation and management of strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amblyopia is a functional reduction in the visual acuity of an eye caused by disuse or misuse during the critical period of visual development. The mechanism of vision loss is not known, but it is thought to originate in the central nervous system. Disuse or misuse typically occurs because of strabismus, unequal refractive errors (anisometropia), or deprivation (eg, caused by cataract, ptosis, eyelid hemangioma, etc). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One author describes three critical periods in the development of visual acuity and amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The period of development of visual acuity (from birth to three to five years of age) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H2#H2\">",
"       \"Visual development and vision assessment in infants and children\", section on 'Visual development'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The period during which deprivation may cause amblyopia (from a few months to seven or eight years of age)",
"     </li>",
"     <li>",
"      The period during which recovery from amblyopia can be obtained (from the time of deprivation to adolescence or young adulthood)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of amblyopia is estimated to be between 1 and 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Estimates of prevalence are affected by the definition of reduced visual acuity and by the process of early screening and treatment in the population being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/6,11-13\">",
"     6,11-13",
"    </a>",
"    ]. Amblyopia occurs with equal frequency in boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/14\">",
"     14",
"    </a>",
"    ]. In some series, the left eye was more commonly affected than was the right, particularly in cases of anisometropic amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean age at presentation of amblyopia varies by the type [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In a series of 961 children, the mean ages of presentation for anisometropic, strabismic, and mixed amblyopia were 5.6, 3.3, and 4.4 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/14\">",
"     14",
"    </a>",
"    ]. The reported upper age limit for the development of amblyopia in children who are exposed to an amblyopia-inducing condition (eg, traumatic cataract) ranges from 6 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amblyopia is classified by the presence of associated clinical findings. The three main types are [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strabismic amblyopia",
"     </li>",
"     <li>",
"      Anisometropic or refractive amblyopia",
"     </li>",
"     <li>",
"      Deprivational amblyopia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Strabismic amblyopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strabismic amblyopia results from abnormal binocular interaction. This abnormal interaction causes the foveas of the two eyes to be presented with different and unfusable images. The visual cortex suppresses the image from one eye; long-term suppression results in amblyopia.",
"   </p>",
"   <p>",
"    Surgery to correct the strabismus is ineffective as a treatment of strabismic amblyopia. Surgical realignment of the eyes is usually deferred until amblyopia has been treated. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation and management of strabismus in children\", section on 'Overview of management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anisometropic amblyopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to strabismic amblyopia, in anisometropic amblyopia, the foveas of the two eyes also are presented with different images. However, in anisometropic amblyopia, the differing images are caused by unequal refractive errors; the image in one eye is less well focused on the fovea.",
"   </p>",
"   <p>",
"    Refractive amblyopia occurs most commonly in hyperopic patients, but it may occur in patients with myopia or astigmatism. Refractive amblyopia can develop in both eyes when a severe bilateral refractive error is present, a condition known as ametropic amblyopia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"     \"Refractive errors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the other types of amblyopia, refractive amblyopia may not be detected until the child is old enough to have vision screening performed by the primary care provider or the school system. Children with refractive amblyopia typically lack obvious external abnormalities of the eyes (eg, cataracts, strabismus), and their visual function appears normal because they typically see well with one eye. Refractive amblyopia may be overlooked on initial testing if the crowding phenomenon is not accounted for. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Crowding phenomenon'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Refractive amblyopia, unless severe, usually is readily treatable. Some improvement may be seen even if the diagnosis is made or treatment initiated in older children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Deprivational amblyopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deprivation amblyopia is the least common and most serious type of amblyopia. It is caused by visual deprivation, typically a result of occlusion of the visual axis or severe distortion of the foveal image. Congenital cataracts, ptosis, congenital corneal opacities, vitreous hemorrhage, and severe refractive errors may cause deprivation amblyopia. Deprivation amblyopia results in permanent visual impairment if it is not treated urgently in infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link&amp;anchor=H14#H14\">",
"     \"Cataract in children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated amblyopia in young children was studied in 18 four- to six-year-old children who failed to adhere to the prescribed therapy and who were examined approximately one year later [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/19\">",
"     19",
"    </a>",
"    ]. Visual acuity in the amblyopic eye deteriorated in 41 percent, remained unchanged in 55 percent, and improved in one child who wore glasses intermittently.",
"   </p>",
"   <p>",
"    In addition to its effects on visual acuity, amblyopia may affect binocularity and depth perception. Fusion and stereopsis, the central formation of a three-dimensional image from the images perceived by each eye, are dependent upon receiving clear images from each eye simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with severe amblyopia are at increased risk for loss of vision in the nonamblyopic eye [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/21\">",
"     21",
"    </a>",
"    ]. In a population-based study of 370 individuals with unilateral amblyopia, the projected lifetime risk of vision loss was 1.2 percent (95% CI 1.1-1.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/22\">",
"     22",
"    </a>",
"    ]. In 16 percent of patients, vision loss in the nonamblyopic eye was a result of orbital or ocular trauma, highlighting the need for eye protection in patients with severely reduced vision due to amblyopia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amblyopia should be suspected if the vision in the two eyes is unequal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/23\">",
"     23",
"    </a>",
"    ]. The testing used to diagnose amblyopia depends upon the age of the child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preverbal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equality of vision between the eyes in preverbal children is assessed with several simple tests: fixation, alternate occlusion of the eyes, and the vertical prism test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fixation reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of the fixation reflex involves moving a visual target to and fro in the child&rsquo;s visual space. Each eye is tested separately by occluding the non-tested eye. Accuracy is improved if the fixation test is repeated several times. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H10#H10\">",
"     \"Visual development and vision assessment in infants and children\", section on 'Fixation reflex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who have strabismus and equal vision can maintain fixation with either eye and typically have alternating strabismus. Children with strabismus and amblyopia will typically not maintain fixation with the poorer seeing eye when both eyes are uncovered. Detection of unequal vision is more difficult in nonverbal children who do not have strabismus, but the following tests are helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Differential occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential occlusion objection test involves monitoring the child's response to alternate occlusion of the eyes. Children with equal vision should respond equally, or not at all, to alternate occlusion. Children with moderate to severe visual impairment in one eye typically become irritable when the eye with better vision is occluded (",
"    <a class=\"graphic graphic_picture graphicRef52824 \" href=\"UTD.htm?9/0/9219\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The test should be repeated several times because some children become agitated and resist attempts to cover either eye. A strong preference for one eye, indicated by objecting to its occlusion, is highly suggestive of amblyopia in the opposite eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vertical prism test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vertical prism test (VPT) uses a 10- to 14-diopter vertical prism to induce a vertical tropia that facilitates the detection of unequal vision [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/24\">",
"     24",
"    </a>",
"    ]. The test is performed by first holding the prism (with the base down) in front of the child's right eye, causing a vertical tropia. Amblyopia should be suspected if the right eye moves upward to view the displaced image. The test then is repeated with the prism in front of the left eye.",
"   </p>",
"   <p>",
"    Vision is thought to be equal if the child is able to maintain fixation with either eye and shows no preference for one displaced image over the other. Although the test is simple to perform in any setting, pediatric health care providers rarely perform the vertical prism test because they lack the necessary equipment. In addition, studies have shown that the results of fixation preference testing do not always correlate with formal vision testing results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amblyopia is detected in older children during formal visual acuity testing with the Snellen (alphabet) chart or other similar tests. A best corrected visual acuity difference of two or more lines between the eyes (eg,",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    in the left eye and",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    in the right eye) indicates the presence of amblyopia in the poorer performing eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H13#H13\">",
"     \"Visual development and vision assessment in infants and children\", section on 'Optotype tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allen figure cards and other picture optotype tests typically are used to test the vision of younger children or children who are unable to cooperate with testing using the Snellen chart or the tumbling E figures. Allen figures frequently overestimate visual acuity in children with amblyopia and should be used only when other testing measures are not possible. Amblyopia should be suspected when an acuity difference of one line between the eyes is found when Allen cards are used (eg,",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    in the left eye and",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    in the right).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Crowding phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"crowding phenomenon\" must be considered when examining visual acuity in children who may have amblyopia. The crowding phenomenon is defined by the achievement of better visual acuity when optotypes are presented in isolation than when they are presented in a row with other optotypes.",
"   </p>",
"   <p>",
"    Crowding of multiple visual targets shown to a normal eye has minimal effect on visual acuity. However, crowding of visual targets creates significant disturbance for the amblyopic eye and lowers results of visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, using a row of targets provides a more accurate assessment of visual acuity and improved detection of amblyopia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H13#H13\">",
"     \"Visual development and vision assessment in infants and children\", section on 'Optotype tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of children with amblyopia requires the clinical training and experience of an eye specialist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/23\">",
"     23",
"    </a>",
"    ]. The goal of treatment is the achievement of maximal potential visual acuity for an individual patient.",
"   </p>",
"   <p>",
"    Amblyopia may become more difficult to treat in older children. In randomized trials and a meta-analysis, the Pediatric Eye Disease Investigator Group (PEDIG) has demonstrated that amblyopia is more responsive to treatment that is initiated before age seven years than after age seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Nonetheless, about three-fourths of children with previously untreated amblyopia respond to treatment with two or more lines of improvement up to 18 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/30\">",
"     30",
"    </a>",
"    ]. The upper age limit for optimal therapy is considered to be in the range of 9 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/3,19,31,32\">",
"     3,19,31,32",
"    </a>",
"    ]. The American Academy of Ophthalmology recommends that all children be considered for treatment of amblyopia, regardless of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment in older children is discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Treatment of older children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Stepwise treatment of amblyopia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elimination of any visual obstructions (ie, cataracts, ptosis)",
"     </li>",
"     <li>",
"      Correction of significant refractive errors",
"     </li>",
"     <li>",
"      Encouragement of use of the amblyopic eye",
"     </li>",
"     <li>",
"      Observation for and treatment of recurrences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the first two steps are accomplished, the child must be encouraged to use the amblyopic eye. Use of the amblyopic eye is encouraged by discouraging use of the sound eye with an occluding patch or using drugs or glasses to blur vision in the sound eye [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Use of amblyopic eye'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vision correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of visual deprivation must be eliminated in children with deprivation amblyopia before the use of the amblyopic eye can be encouraged. Similarly, significant refractive error must be corrected with glasses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contact lenses in children with amblyopia due to a refractive error. To patch an eye in the treatment of amblyopia is of little benefit if the amblyopic eye remains unable to focus clearly because of uncorrected refractive error. In addition, refractive correction alone may result in resolution of mild to moderate amblyopia in children with untreated anisometropic amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"     \"Refractive errors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Use of amblyopic eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the amblyopic eye is encouraged by occlusion therapy or penalization of the better-seeing eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Occlusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occlusion therapy involves patching the eye with better vision. The eye is patched part-time or full-time, depending upon the age of the child, the cause and severity of the amblyopia, and the preferences of the treating specialist. This process forces use of the amblyopic eye and can result in substantial and long-term improvement in vision of the amblyopic eye.",
"   </p>",
"   <p>",
"    The major disadvantage to occlusion therapy is that children often resist wearing the patch. They may remove it or peel it back enough to allow peeking. Both of these measures may render treatment less effective or completely ineffective. Supervised inpatient occlusion treatment has been shown to be beneficial in the United Kingdom, but it is impractical and not practiced in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/41\">",
"     41",
"    </a>",
"    ]. Suturing or gluing the occluder in place also have been used to increase adherence with occlusion therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], but the long-term effects of these strategies have not been assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The schedule of patching varies depending upon the child's age and the clinician's preference. As a general rule, younger children require less occlusion than do older children. Various patching schedules for severe and moderate amblyopia in children between three and seven years of age have been compared in prospective, randomized, multicenter trials with different durations of patching yielding equivalent improvements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. The comparative regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Full-time patching (23 to 24 hours per day) versus six hours of patching per day, each combined with at least one hour of close-range visual activities during patching, for four months in 175 children with severe amblyopia (visual acuity of",
"      <span class=\"nowrap\">",
"       20/100",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       20/400)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Six hours of patching versus more than six hours of patching for six months in 209 children with moderate amblyopia (visual acuity",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       20/100)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Six versus two hours of patching, each combined with at least one hour of close-range visual activities during patching for four months, in 189 children with moderate amblyopia (visual acuity",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       20/80)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two hours of patching combined with at least one hour of close-range visual activities versus spectacles alone (if needed) for 5 weeks in 180 children with moderate to severe amblyopia (visual acuity",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       20/400)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One reason that similar results are achieved with differing treatment intensity may be that patches are worn for fewer hours than they are prescribed. In a study in which patching regimens were objectively monitored, the patch was actually worn 4.2 and 6.2 hours per day in children for whom it was prescribed for 6 and 12 hours, respectively (not significantly different) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children undergoing occlusion therapy should be followed closely to prevent occlusion amblyopia in the fellow eye [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Penalization therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual blurring, also called \"penalization,\" temporarily handicaps the sound eye, providing a visual advantage to, and encouraging use of, the amblyopic eye. This blurring can be achieved through drugs or spectacles. Pharmacologic penalization is most effective for patients with hyperopia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic penalization &ndash; Pharmacologic penalization is used by most practitioners and is accomplished through the instillation of cycloplegic ophthalmic drops into the sound eye.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       Atropine",
"      </a>",
"      is the agent used most commonly, but",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/24/15747?source=see_link\">",
"       homatropine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/9/34960?source=see_link\">",
"       scopolamine",
"      </a>",
"      are used by some ophthalmologists. The instillation of atropine causes pupillary dilation, temporary paralysis of the ciliary body, and loss of the ability to accommodate. The loss of ability to accommodate reduces the ability of the better-seeing eye to focus, thereby providing the amblyopic eye with a competitive advantage and encouraging its use. Significant long-term improvement in visual acuity of the amblyopic eye is common [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The side effects of cycloplegic agents, all of which are anticholinergic agents, include fever, flushing, dry mouth, behavior changes, and other known anticholinergic effects.",
"      <br/>",
"      <br/>",
"      Atropine penalization and occlusion have had similar efficacy when compared in prospective clinical trials and systematic review [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/28,52-57\">",
"       28,52-57",
"      </a>",
"      ]. As an example, in a large multicenter trial, 419 children younger than seven years with moderate amblyopia (visual acuity in the range of",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       20/100)",
"      </span>",
"      were randomly assigned to receive one drop of 1 percent atropine sulfate or occlusion for a minimum of six hours per day [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/28,53,54\">",
"       28,53,54",
"      </a>",
"      ]. The following results were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adherence to the prescribed treatment was better in the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      group (78 versus 49 percent completed at least 76 percent of the prescribed treatment) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After six months of treatment, visual acuity in the amblyopic eye (measured with the Snellen chart) improved by three lines in similar proportions of both groups (79 percent of the occlusion group and 74 percent of the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      group) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eighteen months after completion of therapy, improvement from baseline in visual acuity in the amblyopic eye was similar in both groups (mean improvement of 3.6 to 3.7 lines), but remained approximately two lines worse than visual acuity in the nonamblyopic eye (mean of",
"      <span class=\"nowrap\">",
"       20/32",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       20/20)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improvement in visual acuity in the amblyopic eye was maintained at age 10 years in both groups (46 percent had an acuity of",
"      <span class=\"nowrap\">",
"       20/25",
"      </span>",
"      or better) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/54\">",
"       54",
"      </a>",
"      ]. However, residual amblyopia occurred even when treatment was initiated between three and seven years of age, which is normally considered within the treatment window.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optical penalization &ndash; Optical penalization involves altering spectacle correction for the better-seeing eye to produce blur, giving the amblyopic eye a competitive advantage. Optical penalization may be used alone, or more typically, in combination with pharmacologic penalization. The disadvantage to isolated optical penalization is that children may avoid the undesired blur by removing or looking over their spectacles. Optical penalization, when used in combination with cycloplegic agents, may be helpful as an adjunct in the management of amblyopia. However, it does not appear to have any advantage over pharmacologic penalization alone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the various treatments for amblyopia is difficult to measure and to compare because of the lack of a standard, accurate, linear test of visual acuity that can be used for children of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, most cases of amblyopia are diagnosed and successfully treated before visual acuity can be measured accurately.",
"   </p>",
"   <p>",
"    A retrospective study examined the outcome of occlusion treatment in 246 children, 167 with strabismic amblyopia and 79 with anisometropic amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/59\">",
"     59",
"    </a>",
"    ]. Successful outcomes (linear acuity",
"    <span class=\"nowrap\">",
"     6/12",
"    </span>",
"    or better) were achieved in 85 percent of the children with strabismic amblyopia and 100 percent of those with anisometropia.",
"   </p>",
"   <p>",
"    Factors correlated with unsuccessful outcome included poor visual acuity at the start of treatment, more than one diopter of anisometropia, hypermetropia of more than three diopters, and fair or poor compliance with the treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/59\">",
"     59",
"    </a>",
"    ]. Neither age at presentation nor age at start of treatment was correlated with outcome in this study. However, other studies have shown better results with early referral [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/29,60\">",
"     29,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adherence to the treatment plan, more likely in younger children, is a critical factor in outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/1,59,61\">",
"     1,59,61",
"    </a>",
"    ]. In a series of 36 children between the ages of 7 and 10 years who were treated with full-time occlusion (standard occlusion, total penalization or occlusive contact lens), final (best) visual acuity for all patients was between",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once visual acuity has been maximally improved, many authors recommend maintenance therapy using occlusion or penalization to prevent recurrence. Maintenance therapy of two hours a day occlusion or weekend",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    penalization usually is continued for 4 to 12 months after cessation of the more extensive treatments used to gain the improvement. Some authors recommend maintenance therapy only until a child is seven to eight years old, the age at which the visual system is essentially mature and recurrent amblyopia is unlikely to recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment of older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper age limit for successful amblyopia therapy in the past was considered to be 9 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/3,19,31,32\">",
"     3,19,31,32",
"    </a>",
"    ]. Whether older children respond to therapy was evaluated in a controlled trial by the Pediatric Eye Disease Investigator Group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/30\">",
"     30",
"    </a>",
"    ]. Children aged 7 to 17 years with amblyopia (visual acuity ranging from",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/400",
"    </span>",
"    in the amblyopic eye) were randomly assigned to receive optical correction alone or optical correction and treatment. Treatment consisted of two to six hours of patching of the nonamblyopic eye per day; in addition, children aged 7 to 12 also underwent pharmacologic blurring. Response was defined as improvement in visual acuity of &ge;2 lines and was assessed every six weeks until there was no further improvement. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-fourth of the patients responded with visual correction alone.",
"     </li>",
"     <li>",
"      Among children aged 7 to 12 years, the response rate was greater in the treatment than the control group (53 versus 25 percent).",
"     </li>",
"     <li>",
"      Among children aged 13 to 17 years, the response rate was similar in the treatment and control groups (25 versus 23 percent, respectively); among the treated children in this age group, the response rate was greater in those who had never been treated for amblyopia than in those who had (47 versus 20 percent)",
"     </li>",
"     <li>",
"      Most patients, including those who responded to treatment, had residual deficits in visual acuity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the improvements in visual acuity were sustained after discontinuation of treatment was not assessed. Without that information and an assessment of the functional benefit of a two-line improvement in visual acuity, it is unknown whether the upper age limit for treatment of amblyopia should be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/63\">",
"     63",
"    </a>",
"    ]. The difficulties inherent in treating older children (eg, lack of adherence to the treatment plan, potential interference of pharmacologic blurring agents on driving and performance of other activities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/30\">",
"     30",
"    </a>",
"    ]) highlight the importance of early identification and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Refractive surgery for amblyopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a small subset of children with amblyopia or amblyogenic levels of refractive error who can be treated with refractive surgery procedures (photorefractive keratectomy, laser in situ keratomileusis, refractive lens exchange, phakic intraocular lenses) with excellent visual outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/64-67\">",
"     64-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe anisometropia with amblyopia &ndash; These children have extremely high refractive error in one eye only. Refractive correction with glasses causes a condition called aniseikonia (difference in image size) such that the eyes cannot function visually together. Secondarily, the children experience asthenopia (eye fatigue, headache) from this correction and most often refuse to wear the glasses. Contact lenses are another option, but they are difficult to insert in uncooperative children, loss is frequent, and they are costly. The consequence of this",
"      <span class=\"nowrap\">",
"       intolerance/noncompliance",
"      </span>",
"      is severe amblyopia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bilateral severe ametropia with amblyopia &ndash; The children with bilateral severe ametropia who refuse to wear glasses typically have neurobehavioral problems, such as autism, genetic disorders, or cerebral palsy, or craniofacial abnormalities such as microtia, that make wearing glasses impractical. These children live in a world of blur, and everything visual is only perceived when it is a few inches from their face. Thus, visual stimuli are frightening, and the children typically are combative and difficult to manage. One author has coined the term \"visual autism\" for this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Unproven therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Systemic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic treatments have been attempted with limited success.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     Carbidopa-levodopa",
"    </a>",
"    provides short-term improvement of visual acuity in the amblyopic and the normal eye. The treatment has been effective in older children who usually are outside the normal age range for treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. However, sustained improvement is minimal when the drug is discontinued. The addition of occlusion therapy to levodopa may increase and maintain improvement in visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Other pharmacologic agents, including citicoline (cytidine-5'-diphosphocholine), are being investigated and may prove beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Vision training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain therapies, including eye movement exercises, vision training, passive occlusion, and methods designed to stimulate or suppress vision using flashing lights or rapidly rotating patterns have not been well investigated and have few data to support their use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome for children who initiate amblyopia treatment before age seven years was described in a follow-up study of 188 children who participated in a multicenter trial comparing patching and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Most patients received some form of amblyopia therapy after the trial ended, but only 12 percent received treatment during the year before the examination at age 10 years. Improvement in visual acuity of the amblyopic eye was maintained at age 10 years, but residual amblyopia was common, as illustrated by the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean amblyopic eye acuity was approximately",
"      <span class=\"nowrap\">",
"       20/32.",
"      </span>",
"     </li>",
"     <li>",
"      Forty-six percent of amblyopic eyes had a visual acuity of",
"      <span class=\"nowrap\">",
"       20/25",
"      </span>",
"      or better.",
"     </li>",
"     <li>",
"      Age younger than five years at the time of enrollment was associated with better visual acuity outcome (mean visual acuity approximately",
"      <span class=\"nowrap\">",
"       20/25",
"      </span>",
"      -2 versus",
"      <span class=\"nowrap\">",
"       20/32).",
"      </span>",
"     </li>",
"     <li>",
"      The mean difference in visual acuity between eyes was two lines.",
"     </li>",
"     <li>",
"      Sixty-four percent of children had a mean difference in visual acuity between eyes of &gt;1 line",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite normal visual acuity, patients with a history of amblyopia may have deficits in perception of images in the real world, poor motor performance, and poor eye-hand coordination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/75-78\">",
"     75-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amblyopia may have long-term psychosocial consequences. In a survey of 25 patients with a history of amblyopia, approximately 50 percent responded that amblyopia interfered with their schooling, work, or lifestyle, and approximately 40 percent responded that it affected their play of sports or influenced their job choices [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8153/abstract/79\">",
"     79",
"    </a>",
"    ]. In addition, compared with control subjects, patients with amblyopia had a greater degree of somatization, obsessive-compulsive behavior, depression, and anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/58/27553?source=see_link\">",
"       \"Patient information: Crossed eyes and lazy eye (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amblyopia is a functional reduction in the visual acuity of an eye caused by disuse or misuse during the critical period of visual development. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amblyopia is classified by the presence of associated clinical findings into three main types: strabismic, anisometric (or refractive), and deprivational. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to its effects on visual acuity, amblyopia affects binocularity and depth perception. Children with severe amblyopia are at increased risk for developing severe visual impairment or blindness if they have loss of vision in the nonamblyopic eye. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Natural history and sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amblyopia should be suspected if the vision in the two eyes is unequal. The testing used to diagnose amblyopia depends upon the age of the child. In preverbal children, asymmetry of vision may be indicated by an abnormal fixation reflex or differential occlusion test (",
"      <a class=\"graphic graphic_picture graphicRef52824 \" href=\"UTD.htm?9/0/9219\">",
"       picture 1",
"      </a>",
"      ). In older children, asymmetric vision is detected through formal visual acuity testing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of amblyopia requires elimination of any visual obstruction and correction of significant refractive error, followed by encouragement of use of the amblyopic eye (through occlusion or penalization therapy), when required. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Earlier treatment and adherence with the",
"      <span class=\"nowrap\">",
"       occlusion/pharmacologic",
"      </span>",
"      regimen may be associated with better outcomes. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/1\">",
"      Lithander J, Sj&ouml;strand J. Anisometropic and strabismic amblyopia in the age group 2 years and above: a prospective study of the results of treatment. Br J Ophthalmol 1991; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/2\">",
"      Levartovsky S, Gottesman N, Shimshoni M, Oliver M. Factors affecting long-term results of successfully treated amblyopia: age at beginning of treatment and age at cessation of monitoring. J Pediatr Ophthalmol Strabismus 1992; 29:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/3\">",
"      Epelbaum M, Milleret C, Buisseret P, Dufier JL. The sensitive period for strabismic amblyopia in humans. Ophthalmology 1993; 100:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/4\">",
"      Hiscox F, Strong N, Thompson JR, et al. Occlusion for amblyopia: a comprehensive survey of outcome. Eye (Lond) 1992; 6 ( Pt 3):300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/5\">",
"      Daw NW. Critical periods and amblyopia. Arch Ophthalmol 1998; 116:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/6\">",
"      Thompson JR, Woodruff G, Hiscox FA, et al. The incidence and prevalence of amblyopia detected in childhood. Public Health 1991; 105:455.",
"     </a>",
"    </li>",
"    <li>",
"     von Noorden CK. Binocular Vision and Ocular Motility, 5th, Mosby, St. Louis 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/8\">",
"      Williams C, Northstone K, Howard M, et al. Prevalence and risk factors for common vision problems in children: data from the ALSPAC study. Br J Ophthalmol 2008; 92:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/9\">",
"      Friedman DS, Repka MX, Katz J, et al. Prevalence of amblyopia and strabismus in white and African American children aged 6 through 71 months the Baltimore Pediatric Eye Disease Study. Ophthalmology 2009; 116:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/10\">",
"      Pai AS, Rose KA, Leone JF, et al. Amblyopia prevalence and risk factors in Australian preschool children. Ophthalmology 2012; 119:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/11\">",
"      Eibschitz-Tsimhoni M, Friedman T, Naor J, et al. Early screening for amblyogenic risk factors lowers the prevalence and severity of amblyopia. J AAPOS 2000; 4:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/12\">",
"      K&ouml;hler L, Stigmar G. Visual disorders in 7-year-old children with and without previous vision screening. Acta Paediatr Scand 1978; 67:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/13\">",
"      Kvarnstr&ouml;m G, Jakobsson P, Lennerstrand G. Visual screening of Swedish children: an ophthalmological evaluation. Acta Ophthalmol Scand 2001; 79:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/14\">",
"      Woodruff G, Hiscox F, Thompson JR, Smith LK. The presentation of children with amblyopia. Eye (Lond) 1994; 8 ( Pt 6):623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/15\">",
"      Sj&ouml;strand J, Abrahamsson M. Risk factors in amblyopia. Eye (Lond) 1990; 4 ( Pt 6):787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/16\">",
"      Keech RV, Kutschke PJ. Upper age limit for the development of amblyopia. J Pediatr Ophthalmol Strabismus 1995; 32:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/17\">",
"      Taylor D. Critical period for deprivation amblyopia in children. Trans Ophthalmol Soc U K 1979; 99:432.",
"     </a>",
"    </li>",
"    <li>",
"     Day S. Normal and abnormal visual development. In: Pediatric Ophthalmology, Taylor D (Ed), Blackwell Scientific Publications, Cambridge, MA 1990. p.7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/19\">",
"      Simons K, Preslan M. Natural history of amblyopia untreated owing to lack of compliance. Br J Ophthalmol 1999; 83:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/20\">",
"      Magramm I. Amblyopia: etiology, detection, and treatment. Pediatr Rev 1992; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/21\">",
"      Woodruff G. Amblyopia: could we do better? BMJ 1995; 310:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/22\">",
"      Rahi J, Logan S, Timms C, et al. Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study. Lancet 2002; 360:597.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Ophtalmology Pediatric Ophthalmology/Strabismus Panel. Preferred Practice Pattern Guidelines. Amblyopia. American Academy of Ophthalmology, San Francisco 2007 www.aao.org/ppp (Accessed on February 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/24\">",
"      Wright KW, Walonker F, Edelman P. 10-Diopter fixation test for amblyopia. Arch Ophthalmol 1981; 99:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/25\">",
"      Friedman DS, Katz J, Repka MX, et al. Lack of concordance between fixation preference and HOTV optotype visual acuity in preschool children: the Baltimore Pediatric Eye Disease Study. Ophthalmology 2008; 115:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/26\">",
"      Cotter SA, Tarczy-Hornoch K, Song E, et al. Fixation preference and visual acuity testing in a population-based cohort of preschool children with amblyopia risk factors. Ophthalmology 2009; 116:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/27\">",
"      Morad Y, Werker E, Nemet P. Visual acuity tests using chart, line, and single optotype in healthy and amblyopic children. J AAPOS 1999; 3:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/28\">",
"      Repka MX, Wallace DK, Beck RW, et al. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2005; 123:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/29\">",
"      Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia treatment in children. Arch Ophthalmol 2011; 129:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/30\">",
"      Scheiman MM, Hertle RW, Beck RW, et al. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005; 123:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/31\">",
"      Flynn JT, Schiffman J, Feuer W, Corona A. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc 1998; 96:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/32\">",
"      Assaf AA. The sensitive period: transfer of fixation after occlusion for strabismic amblyopia. Br J Ophthalmol 1982; 66:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/33\">",
"      Cleary M. Efficacy of occlusion for strabismic amblyopia: can an optimal duration be identified? Br J Ophthalmol 2000; 84:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/34\">",
"      Mazow ML, Chuang A, Vital MC, Prager T. 1999 Costenbader Lecture. Outcome study in amblyopia: treatment and practice pattern variations. J AAPOS 2000; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/35\">",
"      France TD, France LW. Optical penalization can improve vision after occlusion treatment. J AAPOS 1999; 3:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/36\">",
"      Simons K, Gotzler KC, Vitale S. Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997; 104:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/37\">",
"      Cotter SA, Pediatric Eye Disease Investigator Group, Edwards AR, et al. Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology 2006; 113:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/38\">",
"      Stewart CE, Moseley MJ, Fielder AR, et al. Refractive adaptation in amblyopia: quantification of effect and implications for practice. Br J Ophthalmol 2004; 88:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/39\">",
"      Writing Committee for the Pediatric Eye Disease Investigator Group, Cotter SA, Foster NC, et al. Optical treatment of strabismic and combined strabismic-anisometropic amblyopia. Ophthalmology 2012; 119:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/40\">",
"      Taylor K, Powell C, Hatt SR, Stewart C. Interventions for unilateral and bilateral refractive amblyopia. Cochrane Database Syst Rev 2012; 4:CD005137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/41\">",
"      Dorey SE, Adams GG, Lee JP, Sloper JJ. Intensive occlusion therapy for amblyopia. Br J Ophthalmol 2001; 85:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/42\">",
"      Arnold RW, Armitage MD, Limstrom SA. Sutured protective occluder for severe amblyopia. Arch Ophthalmol 2008; 126:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/43\">",
"      Rubab S, French D, Levin AV. Glued patches for children resistant to amblyopia occlusion therapy. Arch Ophthalmol 2008; 126:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/44\">",
"      Repka MX. How much amblyopia treatment is enough? Arch Ophthalmol 2008; 126:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/45\">",
"      Holmes JM, Kraker RT, Beck RW, et al. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology 2003; 110:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/46\">",
"      Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with patching in children: experience of the amblyopia treatment study. Am J Ophthalmol 2003; 136:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/47\">",
"      Repka MX, Beck RW, Holmes JM, et al. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol 2003; 121:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/48\">",
"      Wallace DK, Pediatric Eye Disease Investigator Group, Edwards AR, et al. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology 2006; 113:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/49\">",
"      Stewart CE, Stephens DA, Fielder AR, et al. Objectively monitored patching regimens for treatment of amblyopia: randomised trial. BMJ 2007; 335:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/50\">",
"      Simon JW, Parks MM, Price EC. Severe visual loss resulting from occlusion therapy for amblyopia. J Pediatr Ophthalmol Strabismus 1987; 24:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/51\">",
"      Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with atropine in children: experience of the amblyopia treatment study. Am J Ophthalmol 2003; 136:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/52\">",
"      Foley-Nolan A, McCann A, O'Keefe M. Atropine penalisation versus occlusion as the primary treatment for amblyopia. Br J Ophthalmol 1997; 81:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/53\">",
"      Pediatric Eye Disease Investigator Group.. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2002; 120:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/54\">",
"      Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, et al. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Arch Ophthalmol 2008; 126:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/55\">",
"      Tejedor J, Ogallar C. Comparative efficacy of penalization methods in moderate to mild amblyopia. Am J Ophthalmol 2008; 145:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/56\">",
"      Scheiman MM, Hertle RW, Kraker RT, et al. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Arch Ophthalmol 2008; 126:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/57\">",
"      Li T, Shotton K. Conventional occlusion versus pharmacologic penalization for amblyopia. Cochrane Database Syst Rev 2009; :CD006460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/58\">",
"      Pediatric Eye Disease Investigator Group. Pharmacological plus optical penalization treatment for amblyopia: results of a randomized trial. Arch Ophthalmol 2009; 127:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/59\">",
"      Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus 1999; 36:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/60\">",
"      Flynn JT, Woodruff G, Thompson JR, et al. The therapy of amblyopia: an analysis comparing the results of amblyopia therapy utilizing two pooled data sets. Trans Am Ophthalmol Soc 1999; 97:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/61\">",
"      Oliver M, Neumann R, Chaimovitch Y, et al. Compliance and results of treatment for amblyopia in children more than 8 years old. Am J Ophthalmol 1986; 102:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/62\">",
"      Mintz-Hittner HA, Fernandez KM. Successful amblyopia therapy initiated after age 7 years: compliance cures. Arch Ophthalmol 2000; 118:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/63\">",
"      Hunter DG. Treatment of amblyopia in older children. Arch Ophthalmol 2005; 123:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/64\">",
"      Paysse EA, Coats DK, Hussein MA, et al. Long-term outcomes of photorefractive keratectomy for anisometropic amblyopia in children. Ophthalmology 2006; 113:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/65\">",
"      Tychsen L, Hoekel J. Refractive surgery for high bilateral myopia in children with neurobehavioral disorders: 2. Laser-assisted subepithelial keratectomy (LASEK). J AAPOS 2006; 10:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/66\">",
"      Yin ZQ, Wang H, Yu T, et al. Facilitation of amblyopia management by laser in situ keratomileusis in high anisometropic hyperopic and myopic children. J AAPOS 2007; 11:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/67\">",
"      Astle WF, Rahmat J, Ingram AD, Huang PT. Laser-assisted subepithelial keratectomy for anisometropic amblyopia in children: outcomes at 1 year. J Cataract Refract Surg 2007; 33:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/68\">",
"      Leguire LE, Rogers GL, Bremer DL, et al. Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus 1992; 29:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/69\">",
"      Leguire LE, Walson PD, Rogers GL, et al. Levodopa/carbidopa treatment for amblyopia in older children. J Pediatr Ophthalmol Strabismus 1995; 32:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/70\">",
"      Repka MX, Kraker RT, Beck RW, et al. Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Arch Ophthalmol 2010; 128:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/71\">",
"      Leguire LE, Rogers GL, Walson PD, et al. Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS 1998; 2:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/72\">",
"      Mohan K, Dhankar V, Sharma A. Visual acuities after levodopa administration in amblyopia. J Pediatr Ophthalmol Strabismus 2001; 38:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/73\">",
"      Campos EC, Schiavi C, Benedetti P, et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 1995; 233:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/74\">",
"      Campos EC, Bolzani R, Schiavi C, et al. Cytidin-5'-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 1996; 93:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/75\">",
"      Mirabella G, Hay S, Wong AM. Deficits in perception of images of real-world scenes in patients with a history of amblyopia. Arch Ophthalmol 2011; 129:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/76\">",
"      Grant S, Melmoth DR, Morgan MJ, Finlay AL. Prehension deficits in amblyopia. Invest Ophthalmol Vis Sci 2007; 48:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/77\">",
"      Webber AL, Wood JM, Gole GA, Brown B. The effect of amblyopia on fine motor skills in children. Invest Ophthalmol Vis Sci 2008; 49:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/78\">",
"      Niechwiej-Szwedo E, Goltz HC, Chandrakumar M, et al. Effects of anisometropic amblyopia on visuomotor behavior, part 2: visually guided reaching. Invest Ophthalmol Vis Sci 2011; 52:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8153/abstract/79\">",
"      Packwood EA, Cruz OA, Rychwalski PJ, Keech RV. The psychosocial effects of amblyopia study. J AAPOS 1999; 3:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6255 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8153=[""].join("\n");
var outline_f7_61_8153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Strabismic amblyopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anisometropic amblyopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Deprivational amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY AND SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preverbal children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fixation reflex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Differential occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vertical prism test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Older children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Crowding phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vision correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Use of amblyopic eye",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Occlusion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Penalization therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment of older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Refractive surgery for amblyopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Unproven therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Systemic treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Vision training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6255|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/0/9219\" title=\"picture 1\">",
"      Differential occlusion test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/58/27553?source=related_link\">",
"      Patient information: Crossed eyes and lazy eye (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_61_8154="Epidemiology, clinical manifestations, diagnosis and management of mumps";
var content_f7_61_8154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, diagnosis and management of mumps",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/61/8154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8154/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/61/8154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8154/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/61/8154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/61/8154/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/61/8154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mumps virus causes an acute, self-limited, viral syndrome. Prior to the widespread use of an effective vaccine, mumps primarily occurred in young children attending primary grade school; mumps was also a leading cause of viral meningitis and the most common cause of unilateral acquired sensorineural deafness in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/1\">",
"     1",
"    </a>",
"    ]. Sporadic outbreaks have occurred in the United States and Europe; some of these patients have required hospitalizations due to complications of infection.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and management of mumps are discussed below. Issues specifically related to the mumps vaccine (eg, efficacy and complications) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"     \"Mumps virus vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps virus is a single-stranded RNA virus and is a member of the Paramyxovirus genus, which also includes human parainfluenza virus. Humans serve as the only natural host for mumps virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mumps virion possesses a helical core containing the genomic nucleocapsid portion, which is surrounded by an external glycoprotein envelope [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/2\">",
"     2",
"    </a>",
"    ]. The major surface glycoproteins provide two discrete functions: hemagglutination-neuraminidase activity and cell fusion activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Only one mumps serotype has been identified. Primary viral isolation culture techniques use a number of cell types, including monkey kidney cell lines; mumps may be isolated from saliva, cerebrospinal fluid, and urine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps epidemics have occurred worldwide with school-aged children generally serving as the vector for horizontal spread to household family members. Data from the National Health and Nutrition Examination Study (NHANES) from 1999 to 2004 demonstrated that the seroprevalence of antibody to mumps virus is 90 percent, which is at the low end of the estimated seroprevalence rates needed for herd immunity (ie, 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/7\">",
"     7",
"    </a>",
"    ]. Mumps seroprevalence was significantly lower in the 1967 to 1976 birth cohort (86 percent), suggesting that these individuals may be at increased risk of mumps infection upon exposure.",
"   </p>",
"   <p>",
"    Prior to the introduction of vaccination in the United States, the peak incidence of mumps was typically in the late winter to early spring, although sporadic outbreaks have occurred throughout the year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of mumps in the United States declined 99 percent from 1968 to 1993 (152,209 versus 1,692 reported cases) following the approval and introduction of a live, attenuated mumps vaccine in 1967 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, extensive outbreaks of mumps were reported between 1986 and 1987 in persons born between 1967 and 1977 who did not routinely receive mandatory mumps vaccine for school entry; these outbreaks led to a change in peak incidence of cases from five to nine years to 10 to 19 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/8\">",
"     8",
"    </a>",
"    ]. Adults also remained susceptible to mumps with more than 10 percent of cases in 1987 reported in individuals &gt;20 years of age. This led to a revision of the ACIP guidelines to recommend that the first dose of MMR be routinely administered at 12 to 15 months of age with a second dose at four to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/9\">",
"     9",
"    </a>",
"    ]. The ACIP also recommended two doses of MMR for college students. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"     \"Mumps virus vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the decline in United States mumps incidence since 1967 (coincident with an effective vaccine strategy), there have been a number of sporadic mumps outbreaks reported in cohorts of susceptible (unexposed) individuals from military posts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/10\">",
"     10",
"    </a>",
"    ], high schools [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], colleges [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and summer camps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There have also been hospital-based [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] and workplace outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/21\">",
"     21",
"    </a>",
"    ]. These outbreaks have frequently involved older individuals who are at risk for more serious morbidity and for complications requiring hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mumps outbreak occurred in 2011 on a California university campus that did not require proof of MMR vaccination of students prior to enrollment [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/24\">",
"       24",
"      </a>",
"      ]. The presumed source patient was an unvaccinated student who had recently returned from Western Europe, where mumps virus had been circulating. Among 29 cases of mumps, 76 percent occurred among individuals previously vaccinated with two doses of MMR vaccine.",
"     </li>",
"     <li>",
"      A mumps outbreak that began in the New York area in June 2009 was traced to a boy aged 11 years who returned from the United Kingdom, where a mumps outbreak had been occurring [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/17\">",
"       17",
"      </a>",
"      ]. He then attended a summer camp for orthodox Jewish boys where he became symptomatic. Between June 28, 2009 and June 27, 2010, 3502 cases of mumps were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/25\">",
"       25",
"      </a>",
"      ]. The outbreak was largely confined to males aged 7 to 18 years within this religious community. Resulting complications included orchitis, pancreatitis, aseptic meningitis, transient deafness, Bell's palsy and oophoritis. Approximately 89 percent of patients had received two doses of mumps-containing vaccine before the outbreak. Thus, this outbreak occurred in a highly vaccinated population, and most cases developed in previously immunized individuals.",
"     </li>",
"     <li>",
"      In 2006, 45 states reported a total of 5783 confirmed or probable cases of mumps [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Parotitis was reported in 66 percent of patients for whom clinical data were available. Complications included orchitis, meningitis, encephalitis, and deafness. The identified mumps strain was genotype G, the same genotype that caused an outbreak in the UK involving more than 70,000 individuals between 2004 and 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/28\">",
"       28",
"      </a>",
"      ]. Among the 1192 patients who were evaluated for their immunization status in Iowa, where the largest number of cases occurred, 6 percent were unvaccinated, 12 percent had received one dose of MMR vaccine, 51 percent had received two doses of MMR, and 31 percent did not have vaccination records.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Worldwide",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3134239\">",
"    <span class=\"h3\">",
"     Immunization practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on a 1998 update from the World Health Organization (WHO), mumps vaccine is routinely utilized by national immunization programs in 82",
"    <span class=\"nowrap\">",
"     countries/areas:",
"    </span>",
"    23 (92 percent) of 25 developed countries, 19 (86 percent) of 22 countries with economies in transition (Newly Independent States of the former Soviet Union), and 40 (24 percent) of 168 developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/29\">",
"     29",
"    </a>",
"    ]. The impact of mumps-associated complications and fatal outcomes in susceptible individuals in developing countries remains an area of public health concern and warrants ongoing surveillance and intensive large scale MMR vaccination programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;During 2004, the number of confirmed cases of mumps increased dramatically in all regions across England and Wales (8104 compared to 3907 cases in the previous five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/16,30\">",
"     16,30",
"    </a>",
"    ]. Mumps occurred in older teenagers and young adults born before 1987. Some of these patients may have received only one dose of MMR as part of a \"catch up\" immunization program after the availability of vaccine in 1988. In contrast, only 2.4 percent of confirmed cases occurred in children born between 1993 and 1999, when two doses of mumps vaccine were offered routinely.",
"   </p>",
"   <p>",
"    The health service, investigating an outbreak of confirmed mumps cases which occurred primarily in adolescents and young adults in Scotland during 2003 and 2004, determined that transmission was greatly facilitated in enclosed settings, such as high schools and universities in which social interactions were frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps is highly infectious and spreads rapidly among susceptible people living in close quarters. Mumps virus is typically transmitted by respiratory droplets, direct contact, or fomites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/32\">",
"     32",
"    </a>",
"    ]. Infants less than one year rarely acquire mumps due to passage of maternal antibodies.",
"   </p>",
"   <p>",
"    The incubation period is usually 14 to 18 days from exposure to onset of symptoms. Viral shedding in respiratory secretions precedes the onset of symptomatic illness and the period of peak contagion is just before the onset of parotitis (approximately three days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A committee composed of members from the CDC, the American Academy of Pediatrics, and the Healthcare Infection Control Practices Advisory Committee reviewed data on viral isolation and shedding during infection to determine the optimal number of days of required isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/34\">",
"     34",
"    </a>",
"    ]. During the 2006 Iowa outbreak, viral shedding generally decreased rapidly after the onset of symptoms; only 4 percent of patients still shed virus on day nine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/35\">",
"     35",
"    </a>",
"    ]. Vaccination status had no appreciable impact on duration of shedding. Another study found that mumps viral load decreased substantially during the first four days of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/36\">",
"     36",
"    </a>",
"    ]. Based on these data, the guideline committee recommended that the isolation duration be shortened from nine days to five days since the risk of transmission after this time is low [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps infection is frequently accompanied by a nonspecific prodrome consisting of low-grade fever, malaise, headache, myalgias, and anorexia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/37\">",
"     37",
"    </a>",
"    ]. These symptoms are generally followed within 48 hours by the development of parotitis, a classic feature of mumps infection. Symptomatic infection in adults is usually more severe than in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Parotitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parotid swelling is present in 95 percent of symptomatic cases of mumps. Parotitis is due to direct infection of ductal epithelium and local inflammation.",
"   </p>",
"   <p>",
"    Local parotid tenderness and occasionally earache precedes the onset of parotid swelling. Enlargement of the contralateral parotid gland occurs in 90 percent of patients, but may be delayed by several days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/38\">",
"     38",
"    </a>",
"    ]. On physical examination, parotid swelling may obscure the angle of the mandible and the orifice of Stensen's duct is erythematous and enlarged (",
"    <a class=\"graphic graphic_picture graphicRef53503 \" href=\"UTD.htm?33/38/34415\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Parotid swelling can last up to 10 days. Increased serum amylase supports the clinical diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inapparent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to these classic manifestations, asymptomatic infection occurs in 15 to 20 percent of cases, and only nonspecific or predominantly respiratory symptoms are seen in up to 50 percent of cases in whom the diagnosis of mumps is not usually made [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/9,39,40\">",
"     9,39,40",
"    </a>",
"    ]. Inapparent or subclinical infections are more frequent in adults, while parotitis is most common in children between the ages of two and nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/39,41\">",
"     39,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more serious complications of mumps, such as meningitis, encephalitis, and orchitis, may occur in the absence of parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/12,15,37\">",
"     12,15,37",
"    </a>",
"    ], which can delay accurate diagnosis of the clinical syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Orchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epididymoorchitis, the most common complication of mumps infection in the adult male, may develop in up to 38 percent of infected postpubertal males [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Symptoms are characterized by the abrupt onset of fever from 39 to 41&ordm;C and severe testicular pain, accompanied by swelling and erythema of the scrotum. The following case series illustrates the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a descriptive series of 67 male patients with orchitis that occurred during a mumps outbreak in the Gran Canaria Island from 2000 to 2001, nearly all patients had onset of fever and parotitis that preceded orchitis by approximately five days [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/44\">",
"       44",
"      </a>",
"      ]. Orchitis was unilateral in approximately 90 percent and bilateral in 10 percent of cases. Fifty-six patients required hospitalization; nine patients also had mumps meningitis. During the follow-up period, a high incidence of sperm abnormalities was observed.",
"     </li>",
"     <li>",
"      In one Swiss outbreak of mumps orchitis documented in 11 men (mean age 32 years, range 17 to 55), all required hospitalization for management of testicular pain, fever (&gt;38.5&ordm;C), and swelling [",
"      <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/45\">",
"       45",
"      </a>",
"      ]. Nine of these patients (82 percent) had mumps parotitis prior to the development of orchitis; the interval between parotitis and the onset of orchitis was 10 days. Patients were hospitalized for an average of six days and were treated with bed rest, nonsteroidal antiinflammatory agents, and local cooling measures. Ten of the 11 patients had never received mumps vaccination; vaccination status of the remaining patient was unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While testicular atrophy has been documented in as many as 30 to 50 percent of patients following mumps orchitis and impaired fertility in approximately 13 percent, sterility is estimated to be rare [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/22,45,46\">",
"     22,45,46",
"    </a>",
"    ]. The risk of sterility is higher in men who have bilateral orchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible association between mumps orchitis and the subsequent development of testicular cancer has been evaluated in several retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/22,48\">",
"     22,48",
"    </a>",
"    ]; to date, no causal link has been definitively established. In a Danish review of 494 cases of testicular cancer in men born between 1941 and 1957, no patient had documented mumps orchitis prior to the diagnosis of testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oophoritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oophoritis occurs in approximately 7 percent of post-pubertal girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aseptic meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic meningitis is the most frequent extrasalivary complication of mumps virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/49\">",
"     49",
"    </a>",
"    ]. Asymptomatic CSF pleocytosis was documented in more than 50 percent of patients with clinical mumps, in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], while clinical aseptic meningitis due to mumps ranged from 4 to 6 percent in larger clinical series of mumps outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/37,52,53\">",
"     37,52,53",
"    </a>",
"    ]. Cases of mumps aseptic meningitis occur three times more often in males than in females [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of meningitis is variable and can occur before, during, or after an episode of mumps parotitis; aseptic meningitis has been reported in 1 to 10 percent of patients with mumps parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/54,56,57\">",
"     54,56,57",
"    </a>",
"    ]. In some series, up to 50 percent of patients present with mumps meningitis in the absence of parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/49,55\">",
"     49,55",
"    </a>",
"    ]. The most frequent manifestations are headache, low grade fever, and mild nuchal rigidity.",
"   </p>",
"   <p>",
"    The CSF profile may have 10 to 2000 white blood cells",
"    <span class=\"nowrap\">",
"     (WBC)/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/51\">",
"     51",
"    </a>",
"    ]. The predominating cells are usually lymphocytes, but an early polymorphonuclear predominance can occasionally be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/55,58\">",
"     55,58",
"    </a>",
"    ]. The CSF total protein is generally normal or mildly elevated. CSF glucose levels can be mildly depressed, but values below 30 to 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/54,55,57\">",
"     54,55,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mumps aseptic meningitis generally has a benign course with full neurologic recovery and no permanent deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link\">",
"     \"Aseptic meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H9#H9\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Other viruses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other neurologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalitis, deafness, Guillain-Barr&eacute; syndrome, transverse myelitis, and facial palsy are other, less frequent, neurologic complications of mumps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-vaccine era, the incidence of mumps encephalitis was estimated to be approximately 1 in 6000 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/52\">",
"     52",
"    </a>",
"    ]; through the 1960s, mumps was the most frequent cause of confirmed viral encephalitis cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/51\">",
"     51",
"    </a>",
"    ]. However, since the implementation of the MMR vaccination program, this incidence has dramatically decreased. In 1981, mumps accounted for only 0.5 percent of cases of viral encephalitis in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/23\">",
"     23",
"    </a>",
"    ]. Similar findings were noted in a review from Finland [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/60\">",
"     60",
"    </a>",
"    ]. After widespread use of MMR vaccine in 1982, mumps encephalitis virtually disappeared.",
"   </p>",
"   <p>",
"    Patients with mumps encephalitis typically present with fever, altered level of consciousness, seizures, paresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/49,54,56,57\">",
"     49,54,56,57",
"    </a>",
"    ]. As many as one-third of patients present without parotitis; as a result, the absence of parotitis does not exclude the diagnosis of mumps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/61\">",
"     61",
"    </a>",
"    ]. The CSF profile is similar to that seen with mumps aseptic meningitis which, as noted above, can occasionally mimic those with bacterial meningitis rather than viral infection (",
"    <a class=\"graphic graphic_table graphicRef76324 \" href=\"UTD.htm?13/55/14204\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with mumps encephalitis make a complete recovery. Cerebellitis and cerebellar ataxia are usually self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/63\">",
"     63",
"    </a>",
"    ]. Hydrocephalus has been rarely been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Deafness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-vaccine era, mumps infection was a prominent cause of sensorineural hearing loss in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. The onset of deafness was often abrupt but occasionally exhibited a more gradual clinical course; bilateral involvement has been reported. Permanent deafness attributable to mumps infection has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/66,68\">",
"     66,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with sensorineural hearing loss during mumps infection have concurrently developed prominent vestibular symptoms. Labyrinthitis and endolymphatic hydrops (Meniere syndrome) also developed subsequently in a patient with prior acute deafness due to mumps infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/69\">",
"     69",
"    </a>",
"    ]. In a 22-year-old man with a recent mumps infection and the onset of sudden deafness and vertigo, enhanced magnetic resonance imaging (MRI) confirmed labyrinthian and cranial nerve VIII nerve bundle involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other neurologic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other neurologic syndromes that have been reported less frequently in patients with mumps infection include Guillain-Barr&eacute; syndrome",
"    <span class=\"nowrap\">",
"     /ascending",
"    </span>",
"    polyradiculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/71-73\">",
"     71-73",
"    </a>",
"    ], transverse myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/74-77\">",
"     74-77",
"    </a>",
"    ] and facial palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Less frequent complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other end organ syndromes occasionally linked to mumps infection include thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/81-83\">",
"     81-83",
"    </a>",
"    ], myocardial involvement, pancreatitis, interstitial nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/84-88\">",
"     84-88",
"    </a>",
"    ], and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps-associated arthropathy is a relatively infrequent complication but affects males more often than females; monoarticular large joint (knee, hip) involvement has been reported in addition to a polyarticular syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/37,90\">",
"     37,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis has occasionally been reported in both children and adults with mumps infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. The clinical course is typically benign, with the majority of cases resolving with conservative management; rarely, pseudocyst formation requiring surgical drainage has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of 49 children who were diagnosed with acute pancreatitis, the most common causes were mumps (39 percent) and trauma (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/92\">",
"     92",
"    </a>",
"    ]. The diagnosis is supported by an elevated serum lipase level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Myocardial involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic changes including depressed ST segments can be seen transiently in up to 15 percent of patients with mumps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/51,94,95\">",
"     51,94,95",
"    </a>",
"    ]. Although rarely encountered, cases of rapidly progressive and fulminant fatal myocarditis with dilated cardiomyopathy attributed to acute infection with mumps have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/96-101\">",
"     96-101",
"    </a>",
"    ]. Most of these myocarditis patients with fatal outcomes developed refractory arrhythmias and congestive heart failure. Coronary artery involvement has also been documented in a case of mumps myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mumps in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps in pregnancy has not been associated with congenital malformations, although the risk of miscarriage with mumps infection is increased during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the patient has parotitis, the diagnosis of mumps is based upon the characteristic clinical features. Leukopenia, with a relative lymphocytosis, and an elevated serum amylase may be noted on routine blood testing.",
"   </p>",
"   <p>",
"    Specific assays for the diagnosis of mumps are more often used in the setting of prominent extrasalivary gland involvement or during a mumps outbreak, when laboratory criteria are necessary to establish accurate incidence figures.",
"   </p>",
"   <p>",
"    Laboratory evidence supportive of a mumps diagnosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/9,103\">",
"     9,103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive IgM mumps antibody",
"     </li>",
"     <li>",
"      Significant rise in IgG titers between acute and convalescent specimens",
"     </li>",
"     <li>",
"      Isolation of mumps virus or nucleic acid from a clinical specimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with classic symptoms of mumps, laboratory confirmation is not required. In patients with more atypical presentations (eg, mumps meningitis) polymerase chain reaction testing of the appropriate fluids enables a rapid diagnosis. Targeted serologic testing may be recommended by the public health department in the setting of a localized outbreak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum IgM antibody testing should be obtained as soon as mumps infection is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/103\">",
"     103",
"    </a>",
"    ]. A second convalescent phase serum sample obtained about two to three weeks after the first sample should be collected. A fourfold or greater increase in IgG titer is considered a positive diagnostic result for mumps. In vaccinated persons with breakthrough disease, IgG titers may rise rapidly and precipitously, which can impair the ability to capture a fourfold rise in serum antibodies. Thus, it is important to obtain the first serum sample soon after clinical presentation.",
"   </p>",
"   <p>",
"    Serum IgM antibody to mumps typically remains positive for up to four weeks but may be negative in up to 50 to 60 percent of specimens from individuals with acute disease who were previously immunized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/104\">",
"     104",
"    </a>",
"    ]. A negative mumps IgM titer in vaccinated individuals, therefore, does not rule out mumps.",
"   </p>",
"   <p>",
"    A positive mumps IgG serology is expected among previously immunized persons; however, the level of neutralizing antibody that is needed for protection against mumps is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/103\">",
"     103",
"    </a>",
"    ]. Serologic tests cannot differentiate between prior exposure to mumps virus or mumps vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with aseptic meningitis due to mumps, the virus can frequently be isolated from the CSF during the first three days of clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/50,56\">",
"     50,56",
"    </a>",
"    ]. Virus is present in saliva for approximately one week, starting two to three days before the onset of parotitis. Virus is also excreted in urine for the first two weeks of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/105\">",
"     105",
"    </a>",
"    ]. However, the selective viral isolation culture techniques are time consuming and may require days to yield a positive identification of mumps virus, thus delaying the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of an IgM antibody capture immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/106\">",
"     106",
"    </a>",
"    ] or a nested polymerase chain reaction (PCR) assay enables more rapid confirmation of mumps in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. A nested mumps reverse transcriptase (RT) PCR assay using a specific 122 bp fragment proved capable of detecting 0.001 plaque forming units",
"    <span class=\"nowrap\">",
"     (PFU)/mL",
"    </span>",
"    of mumps virus in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/107\">",
"     107",
"    </a>",
"    ]. Mumps virus RNA was detected in all 18 CSF samples confirmed by viral isolation techniques. Overall, PCR confirmed mumps virus RNA in the CSF of 96 percent of patients compared to 39 percent for CSF culture alone.",
"   </p>",
"   <p>",
"    The RT-PCR assay has enhanced characterization of genomically discrete mumps strains associated with sporadic outbreaks and serves as a particularly useful tool when applied to epidemiologic surveillance. Use of mumps RT-PCR assay in various clinical specimens (ie, saliva, urine, CSF) provides an efficient method to differentiate distinct mumps strains circulating during a given outbreak and also facilitates distinguishing wild-type stains from vaccine-derived mumps strains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/110-112\">",
"     110-112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of bilateral parotitis, the clinical diagnosis is usually straightforward. Other causes of unilateral or bilateral parotitis include other viral infections (parainfluenza, coxsackievirus, influenza A, Epstein-Barr virus, adenovirus, HIV, cytomegalovirus) and bacterial infections, particularly Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/113\">",
"     113",
"    </a>",
"    ]. Noninfectious etiologies include salivary calculi, tumors, sarcoid, Sj&ouml;gren&rsquo;s syndrome, and thiazide diuretics.",
"   </p>",
"   <p>",
"    Immunization against mumps is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"     \"Mumps virus vaccine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for mumps parotitis is symptomatic and includes analgesics or antipyretics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Topical application of warm or cold packs to the parotid may also be soothing.",
"   </p>",
"   <p>",
"    Patients who have meningitis or pancreatitis with nausea and vomiting may require hospitalization for intravenous fluids.",
"   </p>",
"   <p>",
"    Patients with orchitis are also treated symptomatically with bed rest, nonsteroidal antiinflammatory agents, support of the inflamed testis, and ice packs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of transmission of mumps to others is dependent on early diagnosis, isolation of the infected patient, and immunization of susceptible exposed individuals. Since the introduction of vaccine, mumps cases have declined by 96 percent in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Isolation of infectious patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the management of mumps include isolation until the parotid swelling has resolved to prevent the spread of infection to susceptible persons. Patients with mumps should stay home from school or work for five days after onset of clinical symptoms, as recommended by the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), and the Healthcare Infection Control Practices Advisory Committee (HICPAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/34\">",
"     34",
"    </a>",
"    ]. The CDC, AAP, and HICPAC recommend use of droplet precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/115\">",
"     115",
"    </a>",
"    ]. However, it is important to note that the virus is present in saliva days before clinical parotitis occurs and viral shedding can occur in asymptomatic persons, often making control measures quite difficult.",
"   </p>",
"   <p>",
"    Factors that contribute to local outbreaks of mumps include closed environments (eg, college dormitories) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/116\">",
"     116",
"    </a>",
"    ] and a delay in recognition of mumps by health care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/26\">",
"     26",
"    </a>",
"    ]. Only 25 states require two doses of MMR vaccine on entrance to college. Furthermore, two doses of vaccine are not 100 percent effective in preventing disease; thus, increasing numbers of susceptible individuals who were not effectively immunized may be sufficient to sustain transmission in outbreak situations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"     \"Mumps virus vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Immunization of susceptible patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first inactivated mumps vaccine was introduced in the 1940s; this formulation was eventually replaced by the attenuated vaccine (ie, Jeryl Lynn strain) in 1967 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active immunization with attenuated mumps virus vaccine is recommended for those who have not been vaccinated in the past, or in those who only received one dose of vaccine. Immunization after exposure has not been demonstrated to be protective, although it is recommended by the CDC; the rationale for vaccination is to decrease the risk of disease with possible future exposures. Recently immunized persons should be educated about the symptoms and signs of illness and be instructed to contact their medical provider should they become sick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Evidence of immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP issued new guidelines for mumps vaccination after reviewing data on the 2006 outbreak and previous data on mumps vaccine effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/117\">",
"     117",
"    </a>",
"    ]. Acceptable presumptive evidence of adequate vaccination now requires two doses of vaccine (instead of one) in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      School-aged children (K-12)",
"     </li>",
"     <li>",
"      Adults considered at high risk (eg, persons who work in healthcare facilities, international travelers, and students at post-high school education institutions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In outbreak situations a second dose of vaccine should be considered in exposed children (ages 1-4) and adults. Two doses of vaccine should also be recommended in healthcare workers born before 1957 who do not have evidence of immunity.",
"   </p>",
"   <p>",
"    A third MMR dose may also be a useful option in an outbreak setting. Following the New York outbreak in 2009-2010, a third dose of MMR vaccine was offered to 2265 eligible students in grades 6 to 12; 81 percent chose to receive a third dose [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/118\">",
"     118",
"    </a>",
"    ]. Mumps attack rates declined from 4.9 percent (three weeks before vaccination) to 0.13 percent (three weeks after vaccination). This report suggests, though does not prove, that a third dose may reduce infections during an outbreak.",
"   </p>",
"   <p>",
"    The persistence of cellular and humoral immunity to mumps virus was evaluated in 50 individuals who had been vaccinated twice with MMR vaccine during early childhood and who had follow-up for more than 21 years after immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/61/8154/abstract/119\">",
"     119",
"    </a>",
"    ]. Compared to a control group who had a history of naturally-acquired immunity to mumps, levels of detectable anti-mumps virus IgG antibodies were lower in the vaccinated group. However, mumps antigen-specific lymphoproliferative responses were detected in 98 percent of all patients, consistent with long persistence of cellular immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Contradictions to vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine should not be administered to pregnant women, immunosuppressed patients, or persons with advanced malignancies. A full discussion of the vaccine's efficacy, risks and benefits, and complications is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"     \"Mumps virus vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/24/11650?source=see_link\">",
"       \"Patient information: Mumps (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=see_link\">",
"       \"Patient information: Parotitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the impressive decline in the incidence of mumps cases since the introduction of vaccine, sporadic mumps outbreaks do occur. These outbreaks frequently involve older individuals who are at risk for more serious morbidity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all persons born after 1957 should be immunized against mumps infection as advised by the ACIP (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"       \"Mumps virus vaccine\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mumps is highly infectious and spreads rapidly among susceptible people living in close quarters. The incubation period is usually 14 to 18 days from exposure to onset of symptoms. The infectious period is from three days before until approximately nine days after onset of symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mumps infection is frequently accompanied by a nonspecific prodrome consisting of low grade fever, malaise, headache, myalgias, and anorexia. These symptoms are generally followed within 48 hours by the development of parotitis, a classic feature of mumps infection. Increased serum amylase supports the clinical diagnosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The more serious complications of mumps, such as meningitis, encephalitis, and orchitis, may occur in the absence of parotitis, which can delay accurate diagnosis of the clinical syndrome. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not performing any specific laboratory testing for mumps antibodies in a patient with a classic presentation of parotitis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Leukopenia, with a relative lymphocytosis, and an elevated serum amylase are supportive findings for the clinical diagnosis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no specific therapies for mumps. Symptomatic therapy for parotitis includes analgesics or antipyretics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . Topical application of warm or cold packs to the parotid gland may also be soothing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have meningitis or pancreatitis with nausea and vomiting may require hospitalization for intravenous fluids. Patients with orchitis may benefit from bed rest, support of the inflamed testis, and use of nonsteroidal antiinflammatory agents and ice packs. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with parotitis should be isolated until the parotid swelling has resolved to prevent the spread of infection to susceptible persons. Patients with mumps should stay home from school or work for five days after onset of clinical symptoms. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are exposed to mumps, careful attention should be paid to immunization guidelines. Any patient not known to be previously immunized with the appropriate doses of vaccine should undergo active immunization, as described above. The local public health officials should also be notified of any active cases of mumps. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard contraindications to mumps vaccine apply in the setting of an outbreak. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link\">",
"       \"Mumps virus vaccine\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/1\">",
"      Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008; 47:1458.",
"     </a>",
"    </li>",
"    <li>",
"     Kleiman MB. Mumps virus. In: Laboratory Diagnosis of Viral Infections, 2nd Edition, Lennette EH (Ed), Marcel Dekker, New York 1992. p.549.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/3\">",
"      Choppin PW, Scheid A. The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses. Rev Infect Dis 1980; 2:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/4\">",
"      HENLE G, DEINHARDT F, GIRARDI A. Cytolytic effects of mumps virus in tissue cultures of epithelial cells. Proc Soc Exp Biol Med 1954; 87:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/5\">",
"      Habel K. Cultivation of mumps virus in the developing chick embryo and its application to the studies of immunity to mumps in man. Pub Health Rep 1945; 60:201.",
"     </a>",
"    </li>",
"    <li>",
"     Deinhardt FW, Shramek GJ. Mumps virus. In: Manual of Clinical Microbiology, Lennette EH, Spaulding EH, Truant JP (Eds), 1974. p.703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/7\">",
"      Kutty PK, Kruszon-Moran DM, Dayan GH, et al. Seroprevalence of antibody to mumps virus in the US population, 1999-2004. J Infect Dis 2010; 202:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/8\">",
"      van Loon FP, Holmes SJ, Sirotkin BI, et al. Mumps surveillance--United States, 1988-1993. MMWR CDC Surveill Summ 1995; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/9\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/10\">",
"      Arday DR, Kanjarpane DD, Kelley PW. Mumps in the US Army 1980-86: should recruits be immunized? Am J Public Health 1989; 79:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/11\">",
"      Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994; 169:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/12\">",
"      Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/13\">",
"      Wharton M, Cochi SL, Hutcheson RH, et al. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988; 158:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/14\">",
"      Sosin DM, Cochi SL, Gunn RA, et al. Changing epidemiology of mumps and its impact on university campuses. Pediatrics 1989; 84:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/15\">",
"      Centers for Disease Control (CDC). Mumps outbreaks on university campuses--Illinois, Wisconsin, South Dakota. MMWR Morb Mortal Wkly Rep 1987; 36:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Mumps epidemic--United kingdom, 2004-2005. MMWR Morb Mortal Wkly Rep 2006; 55:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Update: mumps outbreak - New York and New Jersey, June 2009-January 2010. MMWR Morb Mortal Wkly Rep 2010; 59:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/18\">",
"      Wharton M, Cochi SL, Hutcheson RH, Schaffner W. Mumps transmission in hospitals. Arch Intern Med 1990; 150:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/19\">",
"      Brunell PA, Brickman A, O'Hare D, Steinberg S. Ineffectiveness of isolation of patients as a method of preventing the spread of mumps. Failure of the mumps skin-test antigen to predict immune status. N Engl J Med 1968; 279:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/20\">",
"      Harris RW, Kehrer AF, Isacson P. Relationship of occupations to risk of clinical mumps in adults. Am J Epidemiol 1969; 89:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/21\">",
"      Kaplan KM, Marder DC, Cochi SL, Preblud SR. Mumps in the workplace. Further evidence of the changing epidemiology of a childhood vaccine-preventable disease. JAMA 1988; 260:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/22\">",
"      Beard CM, Benson RC Jr, Kelalis PP, et al. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clin Proc 1977; 52:3.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Mumps surveillance, January 1977-December 1982. Atlanta, US Department of Health and Human Services, US Public Health Service, 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Mumps outbreak on a university campus--California, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/25\">",
"      Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med 2012; 367:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Brief report: update: mumps activity--United States, January 1-October 7, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Mumps epidemic--Iowa, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/28\">",
"      Peltola H, Kulkarni PS, Kapre SV, et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis 2007; 45:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/29\">",
"      Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999; 77:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/30\">",
"      Savage E, Ramsay M, White J, et al. Mumps outbreaks across England and Wales in 2004: observational study. BMJ 2005; 330:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/31\">",
"      Donaghy M, Cameron JC, Friederichs V. Increasing incidence of mumps in Scotland: options for reducing transmission. J Clin Virol 2006; 35:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/32\">",
"      Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005; 330:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Exposure to mumps during air travel--United States, April 2006. MMWR Morb Mortal Wkly Rep 2006; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for isolation of persons with mumps. MMWR Morb Mortal Wkly Rep 2008; 57:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/35\">",
"      Polgreen PM, Bohnett LC, Cavanaugh JE, et al. The duration of mumps virus shedding after the onset of symptoms. Clin Infect Dis 2008; 46:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/36\">",
"      Okafuji T, Yoshida N, Fujino M, et al. Rapid diagnostic method for detection of mumps virus genome by loop-mediated isothermal amplification. J Clin Microbiol 2005; 43:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/37\">",
"      Wharton M, Cochi SL, Williams WW. Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 1990; 4:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/38\">",
"      Hviid A, Rubin S, M&uuml;hlemann K. Mumps. Lancet 2008; 371:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/39\">",
"      Foy HM, Cooney MK, Hall CE, et al. Isolation of mumps virus from children with acute lower respiratory tract disease. Am J Epidemiol 1971; 94:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/40\">",
"      Falk WA, Buchan K, Dow M, et al. The epidemiology of mumps in southern Alberta 1980-1982. Am J Epidemiol 1989; 130:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/41\">",
"      PHILIP RN, REINHARD KR, LACKMAN DB. Observations on a mumps epidemic in a virgin population. Am J Hyg 1959; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/42\">",
"      McGuinness AC, Gall EA. Mumps at army camps in 1943. War Med 1944; 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/43\">",
"      Manson AL. Mumps orchitis. Urology 1990; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/44\">",
"      Ternavasio-de la Vega HG, Boronat M, Ojeda A, et al. Mumps orchitis in the post-vaccine era (1967-2009): a single-center series of 67 patients and review of clinical outcome and trends. Medicine (Baltimore) 2010; 89:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/45\">",
"      Casella R, Leibundgut B, Lehmann K, Gasser TC. Mumps orchitis: report of a mini-epidemic. J Urol 1997; 158:2158.",
"     </a>",
"    </li>",
"    <li>",
"     Phillips CF. Mumps. In: Nelson's Textbook of Pediatrics, Vaughn VC, McKay RJ, Nelson WE (Eds), WB Saunders Co., Philadelphia 1987. p.673.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/47\">",
"      Dejucq N, J&eacute;gou B. Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev 2001; 65:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/48\">",
"      Ehrengut W, Schwartau M. Mumps orchitis and testicular tumours. Br Med J 1977; 2:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/49\">",
"      Azimi PH, Cramblett HG, Haynes RE. Mumps meningoencephalitis in children. JAMA 1969; 207:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/50\">",
"      Bang HO, Bang J. Involvement of the central nervous system in mumps. Acta Med Scand 1943; 113:487.",
"     </a>",
"    </li>",
"    <li>",
"     Baum SG, Litman N. Mumps Virus. In: Principles and Practice of Infectious Diseases, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York 2005. p.2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/52\">",
"      RUSSELL RR, DONALD JC. The neurological complications of mumps. Br Med J 1958; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/53\">",
"      Reed D, Brown G, Merrick R, et al. A mumps epidemic on St. George Island, Alaska. JAMA 1967; 199:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/54\">",
"      Johnstone JA, Ross CA, Dunn M. Meningitis and encephalitis associated with mumps infection. A 10-year survey. Arch Dis Child 1972; 47:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/55\">",
"      Levitt LP, Rich TA, Kinde SW, et al. Central nervous system mumps. A review of 64 cases. Neurology 1970; 20:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/56\">",
"      MCLEAN DM, BACH RD, LARKE RP, MCNAUGHTON GA. MUMPS MENINGOENCEPHALITIS, TORONTO, 1963. Can Med Assoc J 1964; 90:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/57\">",
"      RITTER BS. Mumps meningoencephalitis in children. J Pediatr 1958; 52:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/58\">",
"      Connolly KJ, Hammer SM. The acute aseptic meningitis syndrome. Infect Dis Clin North Am 1990; 4:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/59\">",
"      Nussinovitch M, Volovitz B, Varsano I. Complications of mumps requiring hospitalization in children. Eur J Pediatr 1995; 154:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/60\">",
"      Koskiniemi M, Vaheri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet 1989; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/61\">",
"      Koskiniemi M, Donner M, Pettay O. Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand 1983; 72:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/62\">",
"      Wilfert CM. Mumps meningoencephalitis with low cerebrospinal-fluid glucose, prolonged pleocytosis and elevation of protein. N Engl J Med 1969; 280:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/63\">",
"      Cohen HA, Ashkenazi A, Nussinovitch M, et al. Mumps-associated acute cerebellar ataxia. Am J Dis Child 1992; 146:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/64\">",
"      Oran B, Ceri A, Yilmaz H, et al. Hydrocephalus in mumps meningoencephalitis: case report. Pediatr Infect Dis J 1995; 14:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/65\">",
"      Timmons GD, Johnson KP. Aqueductal stenosis and hydrocephalus after mumps encephalitis. N Engl J Med 1970; 283:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/66\">",
"      VUORI M, LAHIKAINEN EA, PELTONEN T. Perceptive deafness in connectionwith mumps. A study of 298 servicemen suffering from mumps. Acta Otolaryngol 1962; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/67\">",
"      Westmore GA, Pickard BH, Stern H. Isolation of mumps virus from the inner ear after sudden deafness. Br Med J 1979; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/68\">",
"      Hall R, Richards H. Hearing loss due to mumps. Arch Dis Child 1987; 62:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/69\">",
"      Hyd&eacute;n D. Mumps labyrinthitis, endolymphatic hydrops and sudden deafness in succession in the same ear. ORL J Otorhinolaryngol Relat Spec 1996; 58:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/70\">",
"      Comacchio F, D'Eredit&agrave; R, Marchiori C. MRI evidence of labyrinthine and eighth-nerve bundle involvement in mumps virus sudden deafness and vertigo. ORL J Otorhinolaryngol Relat Spec 1996; 58:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/71\">",
"      Duncan S, Will RG, Catnach J. Mumps and Guillain-Barr&eacute; syndrome. J Neurol Neurosurg Psychiatry 1990; 53:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/72\">",
"      Pollack S, Bar-On E, Enat R. Guillain-Barr&eacute; syndrome; association with mumps. N Y State J Med 1981; 81:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/73\">",
"      Tulloch A. Polyneuritis--an unusual complication of mumps. Med J Aust 1973; 1:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/74\">",
"      Venketasubramanian N. Transverse myelitis following mumps in an adult -- a case report with MRI correlation. Acta Neurol Scand 1997; 96:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/75\">",
"      Anand R, Anand R, Gupta M, et al. Mumps hemiplegia. Indian J Pediatr 1997; 64:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/76\">",
"      Nussinovitch M, Brand N, Frydman M, Varsano I. Transverse myelitis following mumps in children. Acta Paediatr 1992; 81:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/77\">",
"      Benady S, Zvi AB, Szabo G. Transverse myelitis following mumps. Acta Paediatr Scand 1973; 62:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/78\">",
"      Beardwell A. Facial palsy due to the mumps virus. Br J Clin Pract 1969; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/79\">",
"      Morgan M, Nathwani D. Facial palsy and infection: the unfolding story. Clin Infect Dis 1992; 14:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/80\">",
"      Djupesland G, Berdal P, Johannessen TA, et al. Viral infection as a cause of acute peripheral facial palsy. Arch Otolaryngol 1976; 102:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/81\">",
"      Hung W. Mumps thyroiditis and hypothyroidism. J Pediatr 1969; 74:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/82\">",
"      Lyon E. [Subacute mumpsthyroiditis and its management]. Med Klin 1967; 62:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/83\">",
"      Sheba C, Bank H. Prevention of mumps thyroiditis. N Engl J Med 1968; 279:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/84\">",
"      Kabaku�� N, Aydino��lu H, Bakkalo��lu SA, Yekeler H. Mumps interstitial nephritis: a case report. Pediatr Nephrol 1999; 13:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/85\">",
"      Lin CY, Chen WP, Chiang H. Mumps associated with nephritis. Child Nephrol Urol 1990; 10:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/86\">",
"      Monteiro GE, Lillicrap CA. Case of mumps nephritis. Br Med J 1967; 4:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/87\">",
"      Masson AM, Nickerson GH. Mumps with nephritis. Can Med Assoc J 1967; 97:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/88\">",
"      Hughes WT, Steigman AJ, Delong HF. Some implications of fatal nephritis associated with mumps. Am J Dis Child 1966; 111:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/89\">",
"      Harel L, Amir J, Reish O, et al. Mumps arthritis in children. Pediatr Infect Dis J 1990; 9:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/90\">",
"      Gordon SC, Lauter CB. Mumps arthritis: a review of the literature. Rev Infect Dis 1984; 6:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/91\">",
"      Suskovi�� T, Vukicevi��-Baudoin D, Vucicevi�� Z, Holjevac I. Severe pancreatitis as first symptom of mumps complicated with pseudocyst and abscess of pancreas. Infection 1997; 25:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/92\">",
"      Haddock G, Coupar G, Youngson GG, et al. Acute pancreatitis in children: a 15-year review. J Pediatr Surg 1994; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/93\">",
"      Parenti DM, Steinberg W, Kang P. Infectious causes of acute pancreatitis. Pancreas 1996; 13:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/94\">",
"      Kussy JC. Fatal mumps myocarditis. Minn Med 1974; 57:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/95\">",
"      Roberts WC, Fox SM 3rd. Mumps of the heart. Clinical and pathologic features. Circulation 1965; 32:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/96\">",
"      Ozkutlu S, Soylemezoglu O, Calikoglu AS, et al. Fatal mumps myocarditis. Jpn Heart J 1989; 30:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/97\">",
"      Baandrup U, Mortensen SA. Fatal mumps myocarditis. Acta Med Scand 1984; 216:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/98\">",
"      Ward SC, Wiselka MJ, Nicholson KG. Still's disease and myocarditis associated with recent mumps infection. Postgrad Med J 1988; 64:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/99\">",
"      Watanabe A, Namura M, Kanaya H, et al. [A case of mumps myocarditis associated with coronary artery involvements]. Nihon Naika Gakkai Zasshi 1987; 76:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/100\">",
"      Chaudary S, Jaski BE. Fulminant mumps myocarditis. Ann Intern Med 1989; 110:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/101\">",
"      Kabaku�� N, Aydino��lu H, Yekeler H, Arslan IN. Fatal mumps nephritis and myocarditis. J Trop Pediatr 1999; 45:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/102\">",
"      Siegel M, Fuerst HT. Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis. JAMA 1966; 197:680.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mumps/lab/qa-lab-test-infect.html#st3 (Accessed on August 22, 2011).",
"    </li>",
"    <li>",
"     Boston Public Health Commission. Health Alert: Mumps Outbreak. April 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/105\">",
"      UTZ JP, HOUK VN, ALLING DW. CLINICAL AND LABORATORY STUDIES OF MUMPS. N Engl J Med 1964; 270:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/106\">",
"      Glikmann G, Pedersen M, Mordhorst CH. Detection of specific immunoglobulin M to mumps virus in serum and cerebrospinal fluid samples from patients with acute mumps infection, using an antibody-capture enzyme immunoassay. Acta Pathol Microbiol Immunol Scand C 1986; 94:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/107\">",
"      Poggio GP, Rodriguez C, Cisterna D, et al. Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases. J Clin Microbiol 2000; 38:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/108\">",
"      Hosoya M, Honzumi K, Sato M, et al. Application of PCR for various neurotropic viruses on the diagnosis of viral meningitis. J Clin Virol 1998; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/109\">",
"      Jeffery KJ, Read SJ, Peto TE, et al. Diagnosis of viral infections of the central nervous system: clinical interpretation of PCR results. Lancet 1997; 349:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/110\">",
"      Cusi MG, Bianchi S, Valassina M, et al. Rapid detection and typing of circulating mumps virus by reverse transcription/polymerase chain reaction. Res Virol 1996; 147:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/111\">",
"      Afzal MA, Buchanan J, Dias JA, et al. RT-PCR based diagnosis and molecular characterisation of mumps viruses derived from clinical specimens collected during the 1996 mumps outbreak in Portugal. J Med Virol 1997; 52:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/112\">",
"      Kashiwagi Y, Kawashima H, Takekuma K, et al. Detection of mumps virus genome directly from clinical samples and a simple method for genetic differentiation of the Hoshino vaccine strain from wild strains of mumps virus. J Med Virol 1997; 52:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/113\">",
"      Davidkin I, Jokinen S, Paananen A, et al. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005; 191:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/114\">",
"      Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/115\">",
"      Kutty PK, Kyaw MH, Dayan GH, et al. Guidance for isolation precautions for mumps in the United States: a review of the scientific basis for policy change. Clin Infect Dis 2010; 50:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/116\">",
"      Bitsko RH, Cortese MM, Dayan GH, et al. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. J Clin Microbiol 2008; 46:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/117\">",
"      Centers for Disease Control and Prevention (CDC). Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps. MMWR Morb Mortal Wkly Rep 2006; 55:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/118\">",
"      Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics 2012; 130:e1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/61/8154/abstract/119\">",
"      Jokinen S, Osterlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis 2007; 196:861.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8310 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-42B8F45CE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8154=[""].join("\n");
var outline_f7_61_8154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Outbreaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Worldwide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3134239\">",
"      - Immunization practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Outbreaks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Parotitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inapparent infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Orchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oophoritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aseptic meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other neurologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Deafness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other neurologic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Less frequent complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Myocardial involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mumps in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Viral culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Polymerase chain reaction assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Isolation of infectious patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Immunization of susceptible patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Evidence of immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Contradictions to vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8310|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/38/34415\" title=\"picture 1\">",
"      Parotid gland swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8310|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/55/14204\" title=\"table 1\">",
"      CSF analysis in CNS infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=related_link\">",
"      Mumps virus vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/24/11650?source=related_link\">",
"      Patient information: Mumps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=related_link\">",
"      Patient information: Parotitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_61_8155="Phenytoin concentrations and clinical signs";
var content_f7_61_8155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenytoin toxicity: Approximate correlation of serum concentration and clinical signs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Serum concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;10 mg/L (40 &micro;mol/L)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-20 mg/L&nbsp;(40-80 &micro;mol/L)&nbsp;",
"        <strong>",
"         (therapeutic)",
"        </strong>",
"       </td>",
"       <td>",
"        Mild nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20-30 mg/L (80-120 &micro;mol/L)",
"       </td>",
"       <td>",
"        Nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-40 mg/L (120-160 &micro;mol/L)",
"       </td>",
"       <td>",
"        Ataxia, slurred speech, nausea, vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-50 mg/L (160-200 &micro;mol/L)",
"       </td>",
"       <td>",
"        Lethargy and confusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;50 mg/L (&gt;200 &micro;mol/L)",
"       </td>",
"       <td>",
"        Coma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8155=[""].join("\n");
var outline_f7_61_8155=null;
var title_f7_61_8156="Palliative Prognostic Index";
var content_f7_61_8156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Palliative Prognostic Index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Prognostic domains",
"       </td>",
"       <td class=\"subtitle1\">",
"        Partial score value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Karnofsky Performance status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-20",
"       </td>",
"       <td class=\"centered\">",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30-50",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;60",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Clinical symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Oral intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Moderately reduced",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Severely reduced",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Normal",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Edema",
"       </td>",
"       <td class=\"centered\">",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dyspnea at rest",
"       </td>",
"       <td class=\"centered\">",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Delirium",
"       </td>",
"       <td class=\"centered\">",
"        4.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Description of the components of the Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. The scores from each prognostic domain are added. A score of 0 to 2.0 was associated with a median survival of 90 days; score of 2.1 to 4.0, 61 days; score &gt;4.0, 12 days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Morita T, Tsundoa J, Inoue S, et al. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Supportive Care Cancer 1999; 7:128. Copyright &copy; 1999 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8156=[""].join("\n");
var outline_f7_61_8156=null;
var title_f7_61_8157="Melanoma 7th TNM staging";
var content_f7_61_8157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Seventh (2010) TNM staging system for cutaneous melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td>",
"       Primary tumor cannot be assessed (eg, curettaged or severely regressed primary)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       Melanoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       T1",
"      </td>",
"      <td class=\"sublist1_start\">",
"       &le;1.0 mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a: without ulceration and mitoses &lt;1/mm",
"       <sup>",
"        2",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b: with ulceration or mitoses &ge;1/mm",
"       <sup>",
"        2",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       T2",
"      </td>",
"      <td class=\"sublist1_start\">",
"       1.01-2.0 mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a: without ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b: with ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       T3",
"      </td>",
"      <td class=\"sublist1_start\">",
"       2.01-4.0 mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a: without ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b: with ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       T4",
"      </td>",
"      <td class=\"sublist1_start\">",
"       &gt;4.0 mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a: without ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b: with ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td>",
"       Patients in whom the regional nodes cannot be assessed (eg, previously removed for another reason)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       No regional metastases detected",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       N1",
"      </td>",
"      <td class=\"sublist1_start\">",
"       One lymph node",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a: micrometastases*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b: macrometastases&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       N2",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Two or three lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a: micrometastases*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b: macrometastases&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       c: in-transit met(s)/satellite(s) without metastatic lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       Four or more metastatic lymph nodes, or matted lymph nodes, or in-transit met(s)/satellite(s) with metastatic lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       No detectable evidence of distant metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1a",
"      </td>",
"      <td>",
"       Metastases to skin, subcutaneous, or distant lymph node, normal serum LDH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1b",
"      </td>",
"      <td>",
"       Lung metastases, normal LDH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1c",
"      </td>",
"      <td>",
"       Metastasis to other visceral metastases with a normal LDH, or any distant metastases and an elevated LDH",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Micrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).",
"     <br>",
"      &bull; Macrometastases are defined as clinically detectable lymph node metastases confirmed by therapeutic lymphadenectomy or when any lymph node metastasis exhibits gross extracapsular extension.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8157=[""].join("\n");
var outline_f7_61_8157=null;
var title_f7_61_8158="Contents: Adult environmental emergencies";
var content_f7_61_8158=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult environmental emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult environmental emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Animal and insect allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28216\">",
"           Insect bites",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Animal bites and stings",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/57/20377\">",
"           Initial management of animal and human bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43016\">",
"           Jellyfish stings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/52/5962\">",
"           Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/48/775\">",
"           Management of Elapidae (coral snake) bites in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19096\">",
"           Marine toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31431\">",
"           Principles of snake bite management worldwide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28038\">",
"           Soft tissue infections due to dog and cat bites",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Burns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4410\">",
"           Environmental electrical injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/27/30136\">",
"           Sunburn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Plant exposures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/44/20168\">",
"           Poison ivy (Toxicodendron) dermatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Temperature extremes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/34/15913\">",
"           Accidental hypothermia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/58/39849\">",
"           Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11594\">",
"           Exertional heat illness in adolescents and adults: Management and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/50/37671\">",
"           Frostbite",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16007\">",
"           Severe hyperthermia (heat stroke) in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Water and altitude",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1130\">",
"           Acute mountain sickness and high altitude cerebral edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4633\">",
"           Complications of scuba diving",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26809\">",
"           Drowning (submersion injuries)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/18/297\">",
"           High altitude illness: Physiology, risk factors, and general prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28936\">",
"           High altitude pulmonary edema",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-46278A6A95-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_61_8158=[""].join("\n");
var outline_f7_61_8158=null;
var title_f7_61_8159="Ankle mortise";
var content_f7_61_8159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal mortise view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mortise view enables assessment for fractures and spacing of the entire joint surface, including that between the fibula and talus. The distance between the talus and either the fibula or tibia should be equal throughout the joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrice Eiff, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_61_8159=[""].join("\n");
var outline_f7_61_8159=null;
